




(86) Date de dépôt PCT/PCT Filing Date: 1999/12/03
(87) Date publication PCT/PCT Publication Date: 2000/06/15
(45) Date de délivrance/Issue Date: 2011/02/01
(85) Entrée phase nationale/National Entry: 2001/06/07
(86) N° demande PCT/PCT Application No.: US 1999/028826
(87) N° publication PCT/PCT Publication No.: 2000/034487
(30) Priorité/Priority: 1998/12/07 (US09/206,898)

(51) Cl.Int./Int.Cl. *C12N 15/57* (2006.01),
A61K 39/09 (2006.01), *C12N 9/52* (2006.01),
A61K 39/00 (2006.01)
(72) Inventeurs/Inventors:
CLEARY, PAUL PATRICK, US;
STAFSLIEN, DEBORAH K., US
(73) Propriétaire/Owner:
REGENTS OF THE UNIVERSITY OF MINNESOTA, US
(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : VACCIN ANTI-STREPTOCOCCIQUE A BASE DE PEPTIDASE C5A
(54) Title: STREPTOCOCCAL C5A PEPTIDASE VACCINE



(57) Abrégé/Abstract:

Novel vaccines for use against β -hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β -hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.




**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/57, 9/52, A61K 39/09	A1	(11) International Publication Number: WO 00/34487 (43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/US99/28826 (22) International Filing Date: 3 December 1999 (03.12.99) (30) Priority Data: 09/206,898 7 December 1998 (07.12.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/206,898 (CIP) Filed on 7 December 1998 (07.12.98) (71) Applicant (for all designated States except US): REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Morrill Hall, 100 Church Street S.E., Minneapolis, MN 55455 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CLEARY, Paul, Patrick [US/US]; 288 Jansa Drive, Shoreview, MN 55112 (US). STAFSLIEN, Deborah, K. [US/US]; Apartment 301, 5680 East River Road, Fridley, MN 55432 (US). (74) Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: STREPTOCOCCAL C5a PEPTIDASE VACCINE



(57) Abstract

Novel vaccines for use against β -hemolytic *Streptococcus* colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β -hemolytic *Streptococcus* colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

STREPTOCOCCAL C5a PEPTIDASE VACCINE**Background of the Invention**

5 There are several different β -hemolytic streptococcal species that have been identified. *Streptococcus pyogenes*, also called group A streptococci, is a common bacterial pathogen of humans. Primarily a disease of children, it causes a variety of infections including pharyngitis, impetigo and sepsis in humans. Subsequent to infection, autoimmune complications such as rheumatic fever and
10 acute glomerulonephritis can occur in humans. This pathogen also causes severe acute diseases such as scarlet fever, necrotizing fasciitis and toxic shock.

 Sore throat caused by group A streptococci, commonly called "strep throat," accounts for at least 16% of all office calls in a general medical practice, depending on the season. Hope-Simpson, E., "Streptococcus pyogenes in the
15 throat: A study in a small population, 1962-1975," L. Hyg. Camb., 87:109-129 (1981). This species is also the cause of the recent resurgence in North America and four other continents of toxic shock associated with necrotizing fasciitis. Stevens, D. L., "Invasive group A streptococcus infections," Clin. Infect. Dis., 14:2-13 (1992). Also implicated in causing strep throat and occasionally in
20 causing toxic shock are groups C and G streptococci. Hope-Simpson, E., "Streptococcus pyogenes in the throat: A study in a small population, 1962-1975," L. Hyg. Camb., 87:109-129 (1981).

 Group B streptococci, also known as *Streptococcus agalactiae*, are responsible for neonatal sepsis and meningitis. T.R. Martin et al., "The effect of
25 type-specific polysaccharide capsule on the clearance of group B streptococci from the lung of infant and adult rats", J. Infect Dis., 165:306-314 (1992). Although frequently a member of vaginal mucosal flora of adult females, from 0.1 to 0.5/1000 newborns develop serious disease following infection during delivery. In spite of the high mortality from group B streptococcal infections,
30 mechanisms of the pathogenicity are poorly understood. Martin, T. R., et al., "The effect of type-specific polysaccharide capsule on the clearance of Group B

streptococci from the lung of infant and adult rats," J. Infect. Dis., 165:306-314 (1992).

Streptococcal infections are currently treated by antibiotic therapy. However, 25-30% of those treated have recurrent disease and/or shed the
5 organism in mucosal secretions. At present no means is available to prevent streptococcal infections. Historically, streptococcal vaccine development has focused on the bacterium's cell surface M protein. Bessen, D., et al., "Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci," Infect.
10 Immun., 56:2666-2672 (1988); Bronze, M. S., et al., "Protective immunity evoked by locally administered group A streptococcal vaccines in mice," Journal of Immunology, 141:2767-2770 (1988).

Two major problems will limit the use, marketing, and possibly FDA approval, of an M protein vaccine. First, more than 80 different M serotypes of
15 *S. pyogenes* exist and new serotypes continually arise. Fischetti, V. A., "Streptococcal M protein: molecular design and biological behavior, Clin. Microbiol. Rev., 2:285-314 (1989). Thus, inoculation with one serotype-specific M protein will not likely be effective in protecting against other M serotypes. The second problem relates to the safety of an M protein vaccine. Several
20 regions of the M protein contain antigenic epitopes which are immunologically cross-reactive with human tissue, particularly heart tissue. The N-termini of M proteins are highly variable in sequence and antigenic specificity. Inclusion of more than 80 different peptides, representing this variable sequence, in a vaccine would be required to achieve broad protection against group A streptococcal
25 infection. New variant M proteins would still continue to arise, requiring ongoing surveillance of streptococcal disease and changes in the vaccine composition. In contrast, the carboxyl-termini of M proteins are conserved in sequence. This region of the M protein, however, contains an amino acid sequence which is immunologically cross-reactive with human heart tissue. This
30 property of M protein is thought to account for heart valve damage associated with rheumatic fever. P. Fenderson et al., "Tropomyosinshares immunologic epitopes with group A streptococcal M proteins, J. Immunol. 142:2475-2481 (1989). In an early trial, children who were vaccinated with M protein in 1979

had a ten fold higher incidence of rheumatic fever and associated heart valve damage. Massell, B. F., et al., "Rheumatic fever following streptococcal vaccination, *JAMA*, 207:1115-1119 (1969).

Other proteins under consideration for vaccine development are the
5 erythrogenic toxins, streptococcal pyrogenic exotoxin A and streptococcal pyrogenic exotoxin B. Lee, P. K., et al., "Quantification and toxicity of group A streptococcal pyrogenic exotoxins in an animal model of toxic shock syndrome-like illness," *J. Clin. Microb.*, 27:1890-1892 (1989). Immunity to these proteins could prevent the deadly symptoms of toxic shock, but may not prevent
10 colonization by streptococci.

Thus, there remains a continuing need for an effective means to prevent or ameliorate streptococcal infections. More specifically, a need exists to develop compositions useful in vaccines to prevent or ameliorate colonization of host tissues by streptococci, thereby reducing the incidence of strep throat and
15 impetigo. Elimination of sequelae such as rheumatic fever, acute glomerulonephritis, sepsis, toxic shock and necrotizing fasciitis would be a direct consequence of reducing the incidence of acute infection and carriage of the organism. A need also exists to develop compositions useful in vaccines to prevent or ameliorate infections caused by all β -hemolytic streptococcal species,
20 namely groups A, B, C and G.

Summary of the Invention

The present invention provides a vaccine, and methods of vaccination, effective to immunize a susceptible mammal against β -hemolytic *Streptococcus*. The susceptible mammal could be a human or a domestic animal such as a dog, a
25 cow, a pig or a horse. Such immunization could prevent, ameliorate or reduce the incidence of β -hemolytic *Streptococcus* colonization in the mammal. The vaccine contains an immunogenic amount of streptococcal C5a peptidase (SCP), wherein the SCP is a variant of wild-type SCP in combination with a physiologically-acceptable, non-toxic vehicle.

30 A "variant" of SCP is a polypeptide or oligopeptide SCP that is not completely identical to native SCP. Such a variant SCP can be obtained by altering the amino acid sequence by insertion, deletion or substitution of one or more amino acid. The amino acid sequence of the protein is modified, for

example by substitution, to create a polypeptide having substantially the same or improved qualities as compared to the native polypeptide. The substitution may be a conserved substitution. A "conserved substitution" is a substitution of an amino acid with another amino acid having a similar side chain. A conserved substitution would be a substitution with an amino acid that makes the smallest change possible in the charge of the amino acid or size of the side chain of the amino acid (alternatively, in the size, charge or kind of chemical group within the side chain) such that the overall peptide retains its spacial conformation but has altered biological activity. For example, common conserved changes might be Asp to Glu, Asn or Gln; His to Lys, Arg or Phe; Asn to Gln, Asp or Glu and Ser to Cys, Thr or Gly. Alanine is commonly used to substitute for other amino acids. The 20 essential amino acids can be grouped as follows: alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan and methionine having nonpolar side chains; glycine, serine, threonine, cystine, tyrosine, asparagine and glutamine having uncharged polar side chains; aspartate and glutamate having acidic side chains; and lysine, arginine, and histidine having basic side chains. L. Stryer, Biochemistry (2d ed.) p. 14-15; Lehninger, Biochemistry, p. 73-75.

The amino acid changes are achieved by changing the codons of the corresponding nucleic acid sequence. It is known that such polypeptides can be obtained based on substituting certain amino acids for other amino acids in the polypeptide structure in order to modify or improve antigenic or immunogenic activity. For example, through substitution of alternative amino acids, small conformational changes may be conferred upon a polypeptide which result in increased activity or enhanced immune response. Alternatively, amino acid substitutions in certain polypeptides may be used to provide residues which may then be linked to other molecules to provide peptide-molecule conjugates which retain sufficient antigenic properties of the starting polypeptide to be useful for other purposes.

One can use the hydropathic index of amino acids in conferring interactive biological function on a polypeptide, wherein it is found that certain amino acids may be substituted for other amino acids having similar hydropathic indices and still retain a similar biological activity. Alternatively, substitution of like amino acids may be made on the basis of hydrophilicity, particularly where

the biological function desired in the polypeptide to be generated in intended for use in immunological embodiments. The greatest local average hydrophilicity of a "protein", as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity. U.S. Patent 4,554,101. Accordingly, it is noted that substitutions can be made based on the hydrophilicity assigned to each amino acid.

In using either the hydrophilicity index or hydropathic index, which assigns values to each amino acid, it is preferred to conduct substitutions of amino acids where these values are ± 2 , with ± 1 being particularly preferred, and those with in ± 0.5 being the most preferred substitutions.

The variant SCP comprises at least seven amino acid residues, preferably about 100 to about 1500 residues, and more preferably about 300 to about 1200 residues, and even more preferably about 500 to about 1180 residues, wherein the variant SCP has at least 50%, preferably at least about 80%, and more preferably at least about 90% but less than 100%, contiguous amino acid sequence homology or identity to the amino acid sequence of a corresponding native SCP.

The amino acid sequence of the variant SCP polypeptide corresponds essentially to the native SCP amino acid sequence. As used herein "correspond essentially to" refers to a polypeptide sequence that will elicit a protective immunological response substantially the same as the response generated by native SCP. Such a response may be at least 60% of the level generated by native SCP, and may even be at least 80% of the level generated by native SCP. An immunological response to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to the polypeptide or vaccine of interest. Usually, such a response consists of the subject producing antibodies, B cell, helper T cells, suppressor T cells, and/or cytotoxic T cells directed specifically to an antigen or antigens included in the composition or vaccine of interest.

The SCP may be a variant of SCP from group A *Streptococcus* (SCPA), group B *Streptococcus* (SCPB), group C *Streptococcus* (SCPC) or group G *Streptococcus* (SCPG).

A variant of the invention may include amino acid residues not present in the corresponding native SCP or deletions relative to the corresponding native SCP. A variant may also be a truncated "fragment" as compared to the corresponding native SCP, i.e., only a portion of a full-length protein. For example, the variant SCP may vary from native SCP in that it does not contain a cell wall insert. SCP variants also include peptides having at least one D-amino acid.

The variant SCP of the vaccine may be expressed from an isolated DNA sequence encoding the variant SCP. For example, the variant SCP may vary from native SCP in that it does not contain a signal sequence or a cell wall insert. The DNA may encode the specificity crevice or the catalytic domain. In particular the DNA may encode amino acid residue 130, 193, 295 or 512 of the catalytic domain, or amino acid residues 260, 261, 262, 415, 416 or 417 of the specificity crevice, or encode modifications at such residues. In particular, the DNA may encode SCPA49D130A, SCPA49H193A, SCPA49N295A, SCPA49S512A, SCPA1D130A, SCPA1H193A, SCPA1N295A, SCPA1S512A, SCPBD130A, SCPBH193A, SCPBN295A, SCPBS512A or Δ SCPA49. For the above listing SCPA49H193A means an SCP from group A *Streptococcus* serotype 49, wherein the His at residue number 193 is replaced with Ala. The SCP of the vaccine may lack enzymatic C5ase or peptidase activity. The vaccine may also contain an immunological adjuvant. The vaccine can be used to prevent infection by group A *Streptococcus*, group B *Streptococcus*, group C *Streptococcus* or group G *Streptococcus*. The vaccine may comprise an immunogenic recombinant streptococcal C5a peptidase conjugated or linked to an immunogenic peptide or to an immunogenic polysaccharide. "Recombinant" is defined as a peptide or nucleic acid produced by the processes of genetic engineering. The terms "protein," "peptide" and "polypeptide" are used interchangeably herein.

The streptococcal C5a peptidase vaccine can be administered by subcutaneous or intramuscular injection. Alternatively, the vaccine can be administered by oral ingestion or intranasal inoculation.

The present invention further provides isolated and purified SCP peptides, wherein the SCP is a variant of wild-type SCP and isolated and

purified polynucleotides encoding a variant SCP. For example, the SCP may include amino acid residue 130, 193, 295 or 512 of the catalytic domain, or amino acid residues 260, 261, 262, 415, 416 or 417 of the specificity crevice. The SCP may be SCPA49D130A, SCPA49H193A, SCPA49N295A,
 5 SCPA49S512A, SCPA1D130A, SCPA1H193A, SCPA1N295A, SCPA1S512A, SCPBD130A, SCPBH193A, SCPBN295A, SCPBS512A or ΔSCPA49.

Brief Description of the Drawings

Figure 1. Architecture of C5a peptidase from β-hemolytic streptococci. D indicates an aspartic acid residue; H indicates histidine; S indicates serine; L
 10 indicates leucine; P indicates proline; T indicates threonine; and N indicates asparagine. R₁, R₂, R₃ and R₄ indicate repeated sequences. The numbers indicate the amino acid residue position in the peptidase.

Figure 2. Alignment of the amino acid sequence of SCP from group A streptococci serotype 49 (SEQ ID NO:1), group A streptococci serotype 12 (SEQ
 15 ID NO:2), group B streptococci (SEQ ID NO:3) and group A streptococci serotype 1 (SEQ ID NO:23). The sequences are identical except for the indicated amino acid positions. The triangle (▽) indicates the predicted cleavage point of the signal peptidase. Amino acids predicted to be in the enzyme's active site are marked by asterisks. Deletions in the amino acid sequence are indicated
 20 by dots and are boxed. The asterisks (*) indicate the amino acid residues of the catalytic domain.

Figure 3. Construction of SCP insertion and deletion mutants. Black box indicates deleted region.

Figure 4. Single color FACS analysis. Fluorescence data were analyzed
 25 by gating on PMNs. A second gate was set to count high staining cells defined by the first gate. Air sacs were inoculated with 1×10^6 CFU.

Figure 5. Persistence of Wild-type and SCPA⁻ serotype M49 streptococci following intranasal infection.

Figure 6. Comparison of the ability of SCPA⁻ mutants of serotype M6
 30 Group A streptococcus to colonize mice following intranasal infection. Compares BALB/c mice (ten in each experimental group) inoculated with 2×10^7 CFU of M6 streptococci. Throat swabs were cultured each day on blood agar plates containing streptomycin. Mice were considered positive if plates

contained one β -hemolytic colony. Data were analyzed statistically by the χ^2 test.

Figure 7. Construction of Δ SCPA49 vaccine and immunization protocol.

Figure 8. Rabbit antibody neutralizes SCPA activity associated with
 5 different serotypes. Bar 1 is a positive control and contained rhC5a which was not preincubated before exposure to PMNs. Bar 10 is a control which lacks rhC5a. Whole, intact bacteria, preincubated with normal rabbit serum (bar 2, M1 90-131; bar 4, M6 UAB200; bar 6, M12 CS24; bar 8, M49 CS101) or preincubated with rabbit anti-SCPA49 serum (bar 3, M1 90-131; bar 5, M6
 10 UAB200; bar 7, M12 CS24; bar 9, M49 CS101), were incubated with 20 μ l of 5 μ M rhC5a for 45 minutes. Residual rhC5a was assayed by its capacity to activate PMNs to adhere to BSA-coated microtiter plate wells. Adherent PMNs were stained with crystal violet.

Figure 9. Serum IgG and secretory IgA responses after intranasal
 15 immunization of mice with the purified Δ SCPA49 protein. Serum and saliva levels of SCPA49 specific IgG were determined by indirect ELISA. Sera from each mouse were diluted to 1: 2,560 in PBS; saliva was diluted 1:2 in PBS. Figure 9A shows the sIgA experimental results; Figure 9B shows the IgG experimental results.

20 Figure 10. Comparison of the ability of serotype M49 streptococci to colonize immunized and non-immunized CD1 female mice. Each experimental group contained 13 mice which were infected intranasally (i.n.) with 2.0×10^8 CFU. The data were analyzed statistically by the χ^2 test. Figures 10A and 10B show the results of the repeated experiment.

25 Figure 11. Competitive ELISA Comparison of wild-type and variant SCP binding to polyclonal antibody. Plate antigen is recombinant wild-type SCPA49 (100 ng/well). Competing antigen is indicated by the legend.

Figure 12. Competitive ELISA Comparison of SCPA1, SCPA49 and SCPB binding to polyclonal antibody. Plate antigen is recombinant wild-type
 30 SCPA49 (100 ng/well). Competing antigen is indicated by the legend. SCPA1 and SCPA49 used in the experiments depicted in this Figure comprised Asn³² through His¹¹³⁹. SCPB used in the experiments depicted in this Figure was made

according to Chmouryguina, I. et al., "Conservation of the C5a Peptidase Gene in Group A and B Streptococci", Infect. Immun., 64:2387-2390 (1996).

Detailed Description of the Invention

An important first line of defense against infection by many bacterial
5 pathogens is the accumulation of phagocytic polymorphonuclear leukocytes (PMNs) and mononuclear cells at the site of infection. Attraction of these cells is mediated by chemotactic stimuli, such as host factors or factors secreted by the invading organism. The C5a chemoattractant is pivotal to the stimulation of this inflammatory response in mammals. C5a is a 74 residue glycopeptide cleaved
10 from the fifth component (C5) of complement. Phagocytic cells respond in a directed manner to a gradient of C5a and accumulate at the site of infection. C5a may be the most immediate attractant of phagocytes during inflammation. As PMNs infiltrate an inflammatory lesion they secrete other chemokines, such as IL8, which further intensify the inflammatory response.

15 Streptococcal C5a peptidase (SCP) is a proteolytic enzyme located on the surface of pathogenic streptococci where it destroys C5a, as C5a is locally produced. SCP specifically cleaves the C5a chemotaxin at the PMN binding site (between His⁶⁷-Lys⁶⁸ residues of C5a) and removes the seven most C-terminal residues of C5a. This cleavage of the PMN binding site eliminates the
20 chemotactic signal. Cleary, P., et al., "Streptococcal C5a peptidase is a highly specific endopeptidase," Infect. Immun., 60:5219-5223 (1992); Wexler, D. E., et al., "Mechanism of action of the group A streptococcal C5a inactivator," Proc. Natl. Acad. Sci. USA, 82:8144-8148 (1985).

SCP from group A streptococci is a subtilisin-like serine protease with an
25 M_r of 124,814 da and with a cell wall anchor motif which is common to many Gram positive bacterial surface proteins. The architecture of C5a peptidase is given in Figure 1. The complete nucleotide sequence of the streptococcal C5a peptidase gene of *Streptococcus pyogenes* has been published. Chen, C., and Cleary, P., "Complete nucleotide sequence of the streptococcal C5a peptidase
30 gene of *Streptococcus pyogenes*," J. Biol. Chem., 265:3161-3167 (1990). In contrast to Subtilisins, SCP has a very narrow substrate specificity. This narrow specificity is surprising in light of the marked similarities between their catalytic domains. Cleary, P., et al., "Streptococcal C5a peptidase is a highly specific

endopeptidase," *Infect. Immun.*, 60:5219-5223 (1992). Residues involved in charge transfer are conserved, as are residues on both sides of the binding pocket. However, the remaining amino acid sequence of SCP is unrelated to that of Subtilisins. More than 40 serotypes of Group A streptococci were found to produce SCP protein or to harbor the gene. Cleary, P., et al., "A streptococcal inactivator of chemotaxis: a new virulence factor specific to group A streptococci," in *Recent Advances in Streptococci and Streptococcal Disease* p.179-180 (S. Kotami and Y. Shiokawa ed.; Reedbooks Ltd., Berkshire, England; 1984); Podbielski, A., et al., "The group A streptococcal virR49 gene controls expression of four structural vir regulon genes," *Infect. Immun.*, 63:9-20 (1995).

The catalytic domain or active site of SCP is composed of the charge transfer system and the specificity crevice. The charge transfer system, also called the catalytic domain, contains residues Asp¹³⁰, His¹⁹³, Asn²⁹⁵ and Ser⁵¹² (Figs. 1 and 2). A modification, i.e., a deletion, insertion or substitution, of any one of these amino acids will inactivate the enzyme. The specificity crevice, on the other hand, is predicted to be formed by Ser²⁶⁰, Phe²⁶¹, Gly²⁶², Ile⁴¹⁵, Tyr⁴¹⁶ and Asp⁴¹⁷. Modification by substitution of these amino acids could change the substrate specificity of the enzyme or eliminate proteolytic activity altogether. Modification by deletion of these amino acids would also inactivate the enzyme. The catalytic domain depends on the tertiary structure of the protein that is created when the mature enzyme folds into its active state. This domain is not formed from a contiguous linear array of amino acid residues. Alternatively, modification may also reduce binding of variant SCP to the substrate. Binding may be reduced by 50%, 70% or even 80%.

A C5a peptidase enzyme associated with group B streptococci has also been identified. Hill, H. R., et al., "Group B streptococci inhibit the chemotactic activity of the fifth component of complement," *J. Immunol.* 141:3551-3556 (1988). Restriction mapping and completion of the *scpB* nucleotide sequence showed that *scpB* is 97-98% similar to *scpA*. See Figure 2 for comparison of the amino acid sequence of SCP from group A streptococci serotype 49, group A streptococci serotype 12, group B streptococci and group A streptococci serotype 1 (SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:23,

respectively). More than 30 strains, representing all serotypes of group B streptococci carry the *scpB* gene. Cleary P.P., et al. "Similarity between the Group B and A streptococcal C5a Peptidase genes," Infect. Immun. 60:4239-4244 (1992); Suvorov A.N., et al., "C5a peptidase gene from group B streptococci," in Genetics and Molecular Biology of Streptococci, Lactococci, and Enterococci p. 230-232 (G. Dunny, P. Cleary and L. McKay (ed.); American Society for Microbiology, Washington, D.C.; 1991).

Human isolates of groups G and C streptococci also harbor *scpA*-like genes. Some group G strains were shown to express C5a specific protease activity on their surface. Cleary, P. P., et al., "Virulent human strains of group G streptococci express a C5a peptidase enzyme similar to that produced by group A streptococci," Infect. Immun., 59:2305-2310 (1991). Therefore, all serotypes (>80) of group A streptococci, group B streptococci, group C streptococci and group G streptococci produce the SCP enzyme.

SCP assists streptococci to colonize a potential infection site, such as the nasopharyngeal mucosa, by inhibiting the influx of phagocytic white cells to the site of infection. This impedes the initial clearance of the streptococci by the host. The impact of SCP on inflammation, C5a leukocyte chemotaxis and streptococcal virulence was examined using streptococcal strains with well-defined mutations in the protease structural gene. SCP variants were constructed by targeted plasmid insertion and by replacement of the wild-type gene with *scpA* containing a specific internal deletion. Variants lacked C5a protease activity and did not inhibit the chemotactic response of human or mouse PMNs to C5a in vitro.

A mouse connective tissue air sac model was used to confirm that SCP retards the influx of phagocytic cells and clearance of streptococci from the site of infection. A connective tissue air sac is generated by injecting a small amount of air and PBS (with or without streptococci in it) with a 25-gauge needle under the skin on the back of a mouse. Boyle, M.D.P. et al., "Measurement of leukocyte chemotaxis in vivo," Meth. Enzymol., 162:101:115 (1988). At the end of the experiment, the mice were euthanized by cervical dislocation, the air sacs dissected from the animals, and the air sacs homogenized in buffer. An advantage of the air sac model is that the air sac remains inflated for several days

and free of inflammation, unless an irritant is injected. Thus, injected bacteria and the resulting inflammatory response remains localized over short periods of infection.

The air sac model was modified to compare clearance of wild-type SCP⁺ and SCP⁻ streptococci (i.e., group A streptococci which carried a variant non-functional form of SCP), and to analyze the cellular infiltrate at an early stage of infection. Tissue suspensions were assayed for viable streptococci on blood agar plates and the cellular infiltrate was analyzed by fluorescent cell sorting (FACS). In FACS analysis, individual cells in suspension are labelled with specific fluorescent monoantibodies. Aliquots of labelled cells are injected into a FAC-Scan flowcytometer, or fluorescent cell sorter, which counts cells based on their unique fluorescence. The experiments using the air sac model indicated that streptococci that were SCP⁺ were more virulent than streptococci that were SCP⁻.

A study was performed to measure production of human antibody, both IgG and IgA, against SCP in human sera and saliva. O'Connor, SP, et al., "The Human Antibody Response to Streptococcal C5a Peptidase," *J. Infect. Dis.* 163:109-16 (1991). Generally, sera and saliva from young, uninfected children lacked antibody to SCP. In contrast, most sera and saliva specimens from healthy adults had measurable levels of anti-SCP IgG and SCP-specific secretory IgA (anti-SCP sIgA). Paired acute and convalescent sera from patients with streptococcal pharyngitis possessed significantly higher levels of anti-SCP IgG than did sera from healthy individuals. Sera containing high concentrations of anti-SCP immunoglobulin were capable of neutralizing SCP activity. Detection of this antibody in >90% of the saliva specimens obtained from children who had recently experienced streptococcal pharyngitis demonstrated that children can produce an antibody response.

Even though the human subjects produced IgG and IgA against SCP in response to a natural streptococcal infection, it was not known whether the anti-SCP immunoglobulin provides any protection against infection. Further, it was not known if the SCP protein could act as a vaccine against β -hemolytic streptococcal colonization or infection. First, a study was performed to examine the role of SCP in colonization of the nasopharynx. Following intranasal infection with live group A streptococci, throat cultures were taken daily for up

to ten days. Wild-type and isogenic SCP-deficient mutant streptococci were compared for the ability to persist in the throat over this ten day period. As predicted, the SCP-deficient mutant streptococci were cleared from the nasopharynx more rapidly.

5 The same intranasal mouse model was used to test the capacity of SCP to induce immunity that will prevent colonization. A variant form of the recombinant *scpA49* gene beginning at the nucleotide that encodes Thr⁶³ was cloned. This variant is referred to as ΔSCPA49, and is 2908 bp in length (see Example 4 below). Variant SCP protein was purified from an *E. coli*
10 recombinant by affinity chromatography. Sera from rabbits vaccinated intradermally with this protein preparation neutralized SCP activity in vitro. Purified protein (40 μg) was administered intranasally to mice over a period of five weeks. Immunized mice cleared streptococci in 1-2 days; whereas, throat cultures of non-immunized mice remained positive for up to 10 days. The
15 experiment was repeated on three sets of mice, vaccinated with three separate preparations of a SCP protein.

 Further experiments were performed to determine whether immunization of an animal with a single antigen would prevent colonization by several serotypes. ΔSCPA49 was cloned into an expression vector and expressed in *E.*
20 *coli*. The affinity purified variant ΔSCPA49 protein proved to be highly immunogenic in mice and rabbits. Although the purified variant ΔSCPA49 immunogen lacked enzymatic activity, it induced high titers of rabbit antibodies that were able to neutralize peptidase activity associated with M1, M6, M12 and M49 streptococci *in vitro*. This confirmed that anti-peptidase antibodies lack
25 serotype specificity. Four sets of mice were then intranasally immunized with the purified variant ΔSCPA49 and each was challenged with a different serotype of group A streptococcus. The immunization of mice with ΔSCPA49 protein stimulated significant levels of specific salivary sIgA and serum IgG antibodies and reduced the potential of wild-type M1, M2, M6, M11 and M49 streptococci
30 to colonize. These experiments confirm that immunization with streptococcal C5a peptidase vaccine is effective in preventing the colonization of the nasopharynx.

Experiments were also performed to develop variant SCPs from an M1 OF⁻ strain and from the M49 OF⁺ strain. Since active SCP could be harmful to the host, it was important that the variant proteins lacked enzymatic activity. Amino acids that are required for catalytic activity were replaced with those
5 expected to inactivate the enzyme.

Two properties of the variant proteins were evaluated. First, the specific activities of the wild-type and variant proteins were determined by PMN adherence assay. These experiments indicated that the substituted amino acids reduced enzymatic activity by greater than 90%. Second, the variant proteins
10 were also compared to the wild-type protein for their capacity to bind antibody directed against the wild-type enzyme. Competitive ELISA assays were used for this purpose. The results indicated that the amino acid substitutions did not alter the ability of antibody to bind to the variant proteins.

All earlier protection studies had been performed by administering
15 affinity purified Δ SCPA49 protein intranasally without adjuvant. Intramuscular or subcutaneous (SQ) injection of antigens, however, is historically a preferred, more accepted method of vaccine delivery. Therefore, experiments were performed to test whether SQ injections of Δ SCPA with monophosphoryl lipid A (MPL) and alum (AlPO_4) induced a protective immune response and whether
20 that response reduced colonization when the challenge strain of group A streptococcus differed in serotype from the source of the SCPA vaccine. The capacity of immunized mice to clear streptococci from the oral-nasal pharyngeal mucosa was evaluated by throat culture or by sampling dissected nasal tissue.

The number of streptococci associated with nasal tissue decreased with
25 time, as expected, and the decrease was more rapid and complete in mice immunized with SCPA antigen. The results confirmed that a single SCPA antigen can induce protection against heterologous serotypes. Protection is afforded by antibody that neutralizes peptidase activity on the bacterial surface. This increases the influx of phagocytes within a few hours from the time
30 streptococci are deposited on mucosal tissue. Rapid clearance of streptococci by phagocytes is presumed to prevent subsequent multiplication and persistence of the bacteria. Thus, SQ injection of SCPA antigen with adjuvant consistently induced a vigorous antibody response.

The present invention thus provides a vaccine for use to protect mammals against β -hemolytic *Streptococcus* colonization or infection. In one embodiment of this invention, as is customary for vaccines, the variant streptococcal C5a peptidase can be delivered to a mammal in a pharmacologically acceptable vehicle. Vaccines of the present invention can also include effective amounts of immunological adjuvants, known to enhance an immune response.

The SCP can be conjugated or linked to another peptide or to a polysaccharide. For example, immunogenic proteins well-known in the art, also known as "carriers," may be employed. Useful immunogenic proteins include keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), ovalbumin, human serum albumin, human gamma globulin, chicken immunoglobulin G and bovine gamma globulin. Useful immunogenic polysaccharides include group A *Streptococcal* polysaccharide, C-polysaccharide from group B *Streptococci*, or the capsular polysaccharides of *Streptococcus pneumoniae* or group B *Streptococci*. Alternatively, polysaccharides or proteins of other pathogens that are used as vaccines can be conjugated to, linked to, or mixed with SCP.

Further provided are isolated and purified nucleic acid molecules, e.g., DNA molecules, comprising a preselected nucleic acid segment which encodes at least a portion of a Streptococcal C5a peptidase, i.e., they encode SCP or a variant thereof as described herein, e.g., SCPA49S512A, SCPA49D130A, SCPA49N295A, SCPA1S512A, SCPA1D130A, SCPA1N295A, Δ SCPA49, SCPBS512A, SCPBD130A, SCPBH193A or SCPBN295A, or any combination of these mutations. For example, the invention provides an expression cassette comprising a preselected DNA segment which codes for an RNA molecule which is substantially identical (sense) to all or a portion of a messenger RNA ("target" mRNA), i.e., an endogenous or "native" SCP mRNA. The preselected DNA segment in the expression cassette is operably linked to a promoter. As used herein, "substantially identical" in sequence means that two nucleic acid sequences have at least about 65%, preferably about 70%, more preferably about 90%, and even more preferably about 98%, contiguous nucleotide sequence identity to each other. Preferably, the preselected DNA segment hybridizes under hybridization conditions, preferably under stringent hybridization conditions, to a nucleic acid molecule encoding the corresponding native SCP.

As used herein, "substantially pure" means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, more preferably more than about 85%, about 90%, about 95%, and about 99%. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

As used herein, the term "recombinant nucleic acid" or "preselected nucleic acid," e.g., "recombinant DNA sequence or segment" or "preselected DNA sequence or segment" refers to a nucleic acid, e.g., to DNA, that has been derived or isolated from any appropriate source, that may be subsequently chemically altered *in vitro*, so that its sequence is not naturally occurring, or corresponds to naturally occurring sequences that are not positioned as they would be positioned in a genome which has not been transformed with exogenous DNA. An example of preselected DNA "derived" from a source, would be a DNA sequence that is identified as a useful fragment within a given organism, and which is then chemically synthesized in essentially pure form. An example of such DNA "isolated" from a source would be a useful DNA sequence that is excised or removed from said source by chemical means, e.g., by the use of restriction endonucleases, so that it can be further manipulated, e.g., amplified, for use in the invention, by the methodology of genetic engineering.

Recovery or isolation of a given fragment of DNA from a restriction digest can employ separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. See Lawn et al., Nucleic Acids Res., 9, 6103 (1981), and Goeddel et al., Nucleic Acids Res., 8, 4057 (1980). Therefore, "preselected

DNA" includes completely synthetic DNA sequences, semi-synthetic DNA sequences, DNA sequences isolated from biological sources, and DNA sequences derived from RNA, as well as mixtures thereof.

As used herein, the term "derived" with respect to a RNA molecule
5 means that the RNA molecule has complementary sequence identity to a particular DNA molecule.

Nucleic acid molecules encoding amino acid sequence variants of a SCP are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally
10 occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the SCP.

To immunize a subject, the variant SCP, is administered parenterally, usually by intramuscular or subcutaneous injection in an appropriate vehicle.
15 Other modes of administration, however, such as oral delivery or intranasal delivery, are also acceptable. Vaccine formulations will contain an effective amount of the active ingredient in a vehicle. The effective amount is sufficient to prevent, ameliorate or reduce the incidence of β -hemolytic *Streptococcus* colonization in the target mammal. The effective amount is readily determined
20 by one skilled in the art. The active ingredient may typically range from about 1% to about 95% (w/w) of the composition, or even higher or lower if appropriate. The quantity to be administered depends upon factors such as the age, weight and physical condition of the animal or the human subject considered for vaccination. The quantity also depends upon the capacity of the
25 animal's immune system to synthesize antibodies, and the degree of protection desired. Effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves. The subject is immunized by administration of the SCP in one or more doses. Multiple doses may be administered as is required to maintain a state of immunity to
30 streptococci.

Intranasal formulations may include vehicles that neither cause irritation to the nasal mucosa nor significantly disturb ciliary function. Diluents such as water, aqueous saline or other known substances can be employed with the

subject invention. The nasal formulations may also contain preservatives such as, but not limited to, chlorobutanol and benzalkonium chloride. A surfactant may be present to enhance absorption of the subject proteins by the nasal mucosa.

5 Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be presented dry in tablet form or a product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may
10 include edible oils), or preservative.

 To prepare a vaccine, the purified SCP can be isolated, lyophilized and stabilized. The SCP peptide may then be adjusted to an appropriate concentration, optionally combined with a suitable vaccine adjuvant, and packaged for use. Suitable adjuvants include but are not limited to surfactants,
15 e.g., hexadecylamine, octadecylamine, lysolecithin, dimethyldioctadecylammonium bromide, N,N-dioctadecyl-N'-N-bis(2-hydroxyethyl-propane di-amine), methoxyhexadecyl-glycerol, and pluronic polyols; polyanions, e.g., pyran, dextran sulfate, poly IC, polyacrylic acid, carbopol; peptides, e.g., muramyl dipeptide, MPL, aimethylglycine, tuftsin, oil
20 emulsions, alum, and mixtures thereof. Other potential adjuvants include the B peptide subunits of *E. coli* heat labile toxin or of the cholera toxin. McGhee, J.R., et al., "On vaccine development," Sem. Hematol., 30:3-15 (1993). Finally, the immunogenic product may be incorporated into liposomes for use in a vaccine formulation, or may be conjugated to proteins such as keyhole limpet
25 hemocyanin (KLH) or human serum albumin (HSA) or other polymers.

 The application of SCP for vaccination of a mammal against colonization offers advantages over other vaccine candidates. Prevention of colonization or infection by inoculation with a single protein will not only reduce the incidence of the very common problems of strep throat and impetigo, but will also
30 eliminate sequelae such as rheumatic fever, acute glomerulonephritis, sepsis, toxic shock and necrotizing fasciitis.

 The following examples are intended to illustrate but not limit the invention.

EXAMPLE 1

Construction and *In Vitro* Analysis of Insertion and Deletion Mutants in *scpA49* and *scpA6*

- a) **Bacterial strains and culture conditions.** *S. pyogenes* strain CS101 is a serotype M49, and serum opacity positive (OF⁺) strain. CS159 is a clinical isolate with a deletion which extends through the M gene cluster and *scpA*. A spontaneous, streptomycin resistant derivative of strain CS101, named CS101Sm, was selected by plating streptococci from a stationary phase culture on tryptose blood agar containing streptomycin (200 µg/ml). Streptococcal strains CS210 and CS463 are spontaneous streptomycin resistant derivatives of OF⁺, class II, serotype M2, and M11 strains, respectively. Streptococcal strains 90-131 and UAB200 are spontaneous streptomycin resistant derivatives of OF⁻, class I, serotype M1 and M6 human isolates of group A streptococci, respectively.
- CS101::pG⁺host5 is strain CS101 with pG⁺host5 integrated into the chromosome at an unknown location, but outside *scpA* and the *emm* gene cluster. *Escherichia coli* strain ER1821 (from New England Biolabs, Inc. Beverly, MA) was used as the recipient for the suicide vector, plasmid pG⁺host5. Plasmid pG⁺host5 was obtained from Appligene, Inc. Pleasanton, CA. Streptococci were grown in Todd-Hewitt broth supplemented with 2% neopeptone or 1% yeast extract, or on tryptose agar plates with 5% sheep blood. *E. coli* strain ER1821 containing plasmid pG⁺host5 was grown in LB broth with erythromycin (300 µg/ml). Streptococci with plasmid pG⁺host5 were cultured in Todd-Hewitt broth with 1% yeast extract (THY) containing 1 µg/ml of erythromycin (Erm).
- SCP refers to streptococcal C5a peptidase from β-hemolytic *Streptococcus* generally. SCPA1, SCPA12, SCPA49, SCPA6 are the specific peptidases from group A *Streptococcus* M serotype 1, 12, 49 and 6 strains, respectively. The term *scpA* refers to the gene encoding SCP from group A streptococci. *ScpA1*, *scpA12*, *scpA6* and *scpA49* are the genes encoding the SCPA1, SCPA12, SCPA49 and SCPA6 peptidases. SCPB and *scpB* refer to the peptidase and gene from group B streptococci. The amino acid sequences for SCPA49 (SEQ ID NO:1), SCPA12 (SEQ ID NO:2), SCPA1 (SEQ ID NO:23) and SCPB (SEQ ID NO:3) are given in Figure 2.

b) Construction of *scpA49* insertion mutant. Well-defined insertion mutants of *scpA49* were constructed using plasmid insertion and gene replacement methods. An internal *scpA49* *Bgl*III - *Bam*HI fragment, the insertion target, was ligated into the thermosensitive shuttle vector pG⁺host5 to form
5 plasmid pG::*scpA*1.2 and transformed into *E. coli* ER1821 (Figure 3). The pG⁺host5 vector contains an *E. coli* origin of replication that is active at 39°C, a temperature sensitive Gram positive origin of replication (active at 30°C and inactive at 39°C in streptococci), and an erythromycin resistance gene for selection. High temperature forces the plasmid to integrate into the
10 chromosomal DNA of group A streptococci by homologous recombination at frequencies ranging from 10⁻² to 10⁻³.

Recombinant plasmid DNA pG::*scpA*1.2 was electroporated into CS101 recipient cells. Transformants were selected on THY-agar plates containing 1 µg/ml erythromycin at 30°C. Chromosomal integrants which resulted from
15 recombination between the plasmid insert and the chromosomal *scpA49* were selected by erythromycin resistance at 39°C. Two insertion mutants, M14 and M16, were analyzed. EmrS revertants of strain M14 and M16 were obtained by passage in THY without antibiotic at 30°C and finally plated at 37°C without Erm selection. Colonies that had lost the plasmid were isolated to confirm that
20 the mutant phenotype resulted from insertion of the plasmid into *scpA49*, rather than from a simultaneous unrelated mutation.

c) Construction of the *scpA6* insertion mutants. The *scpA6* insertion mutant AK1.4 was constructed as described in section (b) above. Recombinant plasmid DNA, pG::*scpA*1.2, contains an internal *Bgl*III-*Hind*III fragment of *scpA*
25 gene. This plasmid was electroporated into UAB200 recipient cells and transformants were selected on THY agar plates containing erythromycin at 30°C. A chromosomal integrant of pG::*scpA*1.2, strain AK1.4, which resulted from recombination between the plasmid insert and the chromosomal *scpA6* was selected by growth on agar medium containing erythromycin at 39°C. Insertion
30 into *scpA6* was confirmed by Southern blotting using *scpA* as the probe, and PCR using an M13 universal primer (5'-GTAAAACGACGGCCAGT-3') (SEQ ID NO:6), specific for the plasmid, and an *scpA* For835 primer (5'-

AAGGACGACACATTGCGTA-3') (SEQ ID NO:7), specific for the chromosomal *scpA* of GAS.

d) Introduction of a defined deletion into *scpA* (Figure 3). A mutant strain with a defined deletion internal to *scpA49* was constructed to eliminate the possibility that insertions in *scpA49* could be polar and reduce expression of downstream genes, unknown genes which could also contribute to the organism's virulence. First, a defined deletion in *Bgl*III-*Hind*III fragment of *scpA* was produced by inside-out PCR with primer 1 (5'-GGGGGGGAATTCGTAGCGGGTATCATGGGAC-3'), SEQ ID NO:4, and primer 2 (5'-GGGGGGGAATTCGGGTGCTGCAATATCTGGC-3'), SEQ ID NO:5. Underlined nucleotides correspond to *scpA* sequences with coordinates 2398 and 2322, respectively, and the bold faced nucleotides correspond to a *Eco*RI recognition site. The primers were selected to produce an in-frame deletion in the *scpA* gene. These primers copy plasmid DNA in opposite directions and define the boundaries of the deletion. Innis, M.A., et al., eds., PCR Protocols A Guide to Methods and Applications (Academic Press, 1990). Plasmid pG::*scpA*1.2 DNA was used as template.

The amplified product was digested with *Eco*RI and ligated to plasmid pG⁺host5. The resulting plasmid pG::Δ*scpA*1.1 contained an 76 bp deletion internal to *scpA*. This in-frame deletion removed 25 amino acids, including the serine which forms part of the predicted catalytic center of serine proteases. Chen, C., and Cleary, P., "Complete nucleotide sequence of the streptococcal C5a peptidase gene of *Streptococcus pyogenes*," J. Biol. Chem., 265:3161-3167 (1990). An *Eco*RV site was created at the point of deletion. DNA which overlaps the deletion was sequenced to confirm the boundaries of the deletion.

The plasmid pG::Δ*scpA*1.1, which contains the deletion, was transformed into *E. coli* ER1821. Colonies were selected for *Erm*R and then screened for the appropriate *scpA* deletion using miniprep plasmid DNA restricted by *Eco*RI. The precise boundaries of the deletion were confirmed by DNA sequencing. Plasmid pG::Δ*scpA*1.1 was electroporated into strain CS101Sm as described above, then integrants were selected by grown on *Erm* at 39°C. Integration of the plasmid into the chromosome of the M49 strain CS101sm using high temperature selection. The insertion location was confirmed by PCR. Growth of

CS101Sm (pG:: $\Delta scpA1.1$) at low temperature without erythromycin selection resulted in high frequency segregation of ErmS revertants which have lost the plasmid by random deletion event or by excision due to recombination between the duplicated *scpA* sequences created by the insertion. Two deletion mutants
5 were identified, MJ2-5 and MJ3-15, and were studied further. The chromosomal deletion left behind by recombinational excision of plasmid pG:: $\Delta scpA1.1$ was defined by PCR and Southern hybridization to EcoRV digested DNA.

e) **In vitro effects of mutations on SCP.** The impact of insertions and deletions on the expression of SCP antigen and peptidase activity was assessed
10 by Western blot and PMNs adherence assays. Streptococci were incubated in 100 ml THY at 37°C overnight. The culture pellet was washed two times in 5 ml cold 0.2 M NaAcetate (pH 5.2), then suspended in 1 ml TE-sucrose buffer (20% sucrose 10 mM Tris, 1 mM EDTA, pH 7.0) and 40 μ l Mutanolysin. The mixture was rotated at 37°C for 2 hr, then centrifuged 5 min at 4500 rpm.
15 Supernatants contained protease inhibitor, 100 mM phenylmethyl sulfonyl fluoride (PMSF). Electrophoresis and Western blotting methods were performed as described in Laemmli, U. K., "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," *Nature* 227:680-685 (1970). The primary antiserum used to detect SCP protein on Western and colony blots was
20 prepared by immunization of a rabbit with purified recombinant SCP protein. Binding was detected by anti-rabbit antibody alkaline phosphatase conjugate.

C5a peptidase activity was measured using a PMN adherence assay. Booth, S. A. et al., "Dapsone suppresses integrin-mediated neutrophil adherence function," *J. Invest. Dermatol.* 98:135-140 (1992). After incubation of C5a
25 (Sigma, St. Louis, MO) with streptococcal extracts or purified protease, residual C5a can activate PMNs to become adherent to BSA coated wells. First, microtiter wells were coated with 0.5% BSA in PBS and incubated for 1 hr at 37°C. Human PMNs were isolated by centrifugation in Ficoll Hypaque (Sigma, St. Louis, MO). 40 μ l of intact streptococci or protein extracts were incubated
30 with 20 μ l of 5 μ M C5a in 340 μ l of PBS with 1% glucose and 0.1% CaCl₂ at 37°C for 45 min. BSA-coated wells were washed with PBS, and resuspended PMNs and residual C5a were added to wells. The mixture was incubated for 45 min at 37°C in 7% CO₂. Finally, wells were washed to remove nonadherent

PMNs. Adherent PMNs were stained with crystal violet and the OD_{570nm} was read in an ELISA reader. The optical density is proportional to the amount of residual C5a or inversely proportional to the amount of SCP activity.

Mutanolysin extracts of cell surface proteins from parent and mutant
5 cultures were analyzed by Western blot using SCPA specific serum. Mutants were confirmed to lack SCPA. Extracts of SCPA⁻ mutants AK1.4 and MJ3-15 did not react with anti-SCPA serum. SCPA proteins of the expected size were observed in extracts from the wild-type strains CS101 and UAB200. Failure of mutant strains AK1.4 and MJ3-15 to produce C5a peptidase activity was verified
10 by comparing their capacity to destroy rhC5a. Exposure of isolated PMNs to rhC5a induced them to become adherent to BSA coated microtiter wells. Incubation with streptococci or purified SCPA specifically cleaved rhC5a and altered its potential to activate PMNs. PMNs that responded to residual rhC5a and bound to BSA coated wells, were stained, then measured
15 spectrophotometrically. Incubation of rhC5a with parent cultures UAB200 and CS101 destroyed rhC5a, which inhibited PMN adherence by 58.8% and 54.5%, respectively. In contrast SCPA⁻ mutants, AK1.4 and MJ3-15, did not alter rhC5a or adherence of PMNs to BSA coated wells (Table 1). This experiment confirmed the Western blots and demonstrated that SCPA⁻ cultures lack other
20 proteases which might degrade rhC5a.

Table 1. Phagocytosis assay and PMN adherence assay of wild-type and mutant strains

Strain	Description	Colony forming units (cfu)/ml		Fold increase in cfu/ml	Percent inhibition of C5a induced PMN adherence*
		Time=0h	Time=3h		
5 UAB200	M6 ⁺ , SCPA ⁺	1.8 x 10 ³	7.2 x 10 ⁴	40	58.8
AK1.4	M6 ⁺ , SCPA ⁻	1.2 x 10 ³	4.5 x 10 ⁴	37.5	0
CS101	M49 ⁺ , SCPA ⁺	1.0 x 10 ⁴	4.9 x 10 ⁵	49	54.5
10 MJ3-15	M49 ⁺ , SCPA ⁻	1.5 x 10 ⁴	2.1 x 10 ⁵	14	0

*Percent inhibition = [(OD_{570nm} of PMNs activated by C5a alone - OD_{570nm} PMNs activated by C5a preincubated with bacteria / OD_{570nm} of PMNs activated by C5a alone)] x 100%.

15 Although M protein expression was not expected to be influenced by mutations in *scpA*, assays were performed to assess whether SCPA⁻ mutant streptococci still expressed M protein and had the ability to resist phagocytosis. Growth of streptococci in fresh human blood during 3 hours incubation is indicative of antiphagocytic M protein on their surface. R.C. Lancefield, 20 "Differentiation of Group A Streptococci with a Common R Antigen into Three Serological Types, with Special Reference to Bactericidal Test," J. Exp. Med., 106, pp. 525-685 (1957). As expected, parent streptococci UAB200 and CS101 increased 40 and 49 fold, respectively (Table 1). The M⁺ SCPA⁻ cultures, strains AK1.4 and MJ3-15, increased 37.5 and 14-fold, respectively, confirming that 25 *scpA* mutations had little effect on M protein expression or resistance to phagocytosis in whole human blood. The somewhat poorer growth of both mutant strains in rotated blood was reproducible and unexpected. The growth rates of mutant and parent cultures in human plasma were indistinguishable. It is possible that inactivation of SCPA allowed C5a to accumulate in rotated blood 30 which in turn activated PMNs. Activated PMNs are more phagocytic and better able to kill M⁺ streptococci. Surface protein extracts contain M6 and M49 antigen when analyzed by Western blot using anti-M49 and anti-M6 antisera, confirming that mutations in SCPA did not alter M protein expression.

EXAMPLE 2**SCP Delays Recruitment of Phagocytes and Clearance of Streptococci from Subdermal Sites of Infection**

In order to verify that SCP was responsible for the inactivation of C5a, the
5 insertion and deletion mutants of *scpA49* were constructed as described in
Example 1 above, and tested for activity. When insertions or deletions were
introduced into *scpA49*, the variant SCP was not able to destroy C5a-activated
adherence of PMNs to microtiter plates.

The impact of mutations in *scpA49* on virulence was tested using an
10 animal model where streptococci remained localized, and where the influx of
inflammatory cells could be analyzed. To test the hypothesis that SCP functions
very early to retard initial clearance of the organism, the fate of SCP⁺ and SCP⁻
streptococci just 4 hours after inoculation of connective tissue air sacs was
compared. Moreover, the dissemination of streptococci to lymph nodes and
15 spleens after this short period of infection was also assessed.

CD1 male outbred mice (25 g) obtained from Charles River Breeding
Laboratory, Wilmington, MA were used for all experiments. A connective tissue
air sac was generated by injecting 0.9 ml of air and 0.1 ml group A streptococci
diluted in PBS with a 25-gauge needle under the skin on the back of the mouse.
20 In some experiments the SCP⁺ CS101::pG⁺host5 was used as a positive control.
In other experiments strain CS101Sm was used as the positive control. Mice
were euthanized by cervical dislocation 4 hours after infection. Where indicated,
all four inguinal lymph nodes, spleen and air sac were dissected from the animals
and homogenized in PBS. Tissue suspensions were assayed for viable colony
25 forming unit (CFU) on blood agar plates containing 1 µg/ml erythromycin or
200 µg/ml streptomycin.

In a preliminary experiment air sacs were fixed on slides, stained with
Wright's stain and examined microscopically. Although counts of granulocytes
by this method were unreliable, there appeared to be significantly fewer residual
30 SCP⁻ than wild-type streptococci in fixed tissue. Additional experiments were
performed in an attempt to measure this difference. Dispersed cell populations
of air sacs were prepared by grinding the air sac in PBS and passing them
through Nylon monofilament mesh (TETKO Co. New York).

The cells were pelleted by centrifugation 5 min at $300 \times g$ and resuspended at $5 \times 10^6/\text{ml}$ in FACS buffer (Hank's balanced salt solution without phenol red, 0.1% NaN_3 , 1.0% BSA fraction V). Cells (1.0×10^6) were stained directly with 1 μg FITC anti-mouse Mac-1 or indirectly with 1 μg Biotin conjugated anti-mouse Gr-1 followed by 1 μg Streptavidin labelled with fluoresce or FITC. Monoclonal antibodies, Mac-1 and Gr-1, were obtained from Pharmingen, Inc. CA. Labeled cells were fixed in 1.0% paraformaldehyde. Fluorescence profiles were generated using a FAC-Scan flowcytometer and Consort 32 software (Becton Dickinson). Mouse PMNs were purified from whole blood by Ficoll Hypaque density gradient centrifugation and used as a standard to defined PMNs in mixed populations. For measurement of specifically labeled cells, the mean fluorescence for each antibody marker was determined and gates were set to reflect intensely labeled cells. Controls included unstained cells, and cells exposed to only streptavidin FITC.

Two experiments were performed. The first compared the *scpA49* insertion mutant M16 to its SCP^+ parent culture, strain CS101. The second compared the *scpA49* deletion mutant MJ3-15, to its parent, strain CS101Sm. (Table 2) In both experiments homogenized air sacs from mice inoculated with SCP^- streptococci contained fewer numbers of streptococci after 4 hours than air sacs inoculated with wild-type streptococci. The first experiment showed a two-fold reduction and the second showed a four-fold reduction. These differences were statistically significant at $P < 0.05$ and $P < 0.001$, respectively, using an Unpaired t-test. It was also observed that wild-type SCP^+ streptococci were found in spleen homogenates from 7 of 8 mice and 6 of 8 mice; whereas, the SCP^- mutants were rarely found in the spleen. The opposite was true for lymph node homogenates. Nodes from 10 of 16 mice infected with SCP^- streptococci harbored viable streptococci; whereas, only 4 of 16 nodes from mice infected with wild-type streptococci contained viable bacteria. This difference was determined to be statistically significant at $P < 0.05$ using the Fisher's exact test.

**Table 2: Distribution of SCP⁺ and SCP⁻ streptococci
4 hours after air sac infection**

Strains	No. of Mice ^a	No. of positive cultures		Homogenized Air Sac ^c
		spleen ^b	lymph node	
5 CS101pG (SCP ⁺)	8	7	2	$1.3 \times 10^8 \pm 2.2 \times 10^7$
M16 (SCP ⁻)	8	0	5	$6.0 \times 10^7 \pm 1.3 \times 10^7$
CS101Sm (SCP ⁺)	8	6	2	$1.6 \times 10^8 \pm 2.6 \times 10^7$
MJ3-15 (SCP ⁻)	8	1	5	$3.7 \times 10^7 \pm 1.5 \times 10^7$

10 ^a Each mouse was inoculated with 3×10^8 CFU of stationary phase streptococci.

^b Difference in the frequency of isolation of SCP⁺ streptococci from spleens relative to SCP⁻ streptococci was statistically significant ($P < 0.05$) for each experiment by the Fisher's exact test.

15 ^c Differences in CFU isolated from homogenized air sacs (means $\pm$ SEMs) were significant, strains CS101pG (SCP⁺) and M16 (SCP⁻) and MJ3-15 (SCP⁻) ($P < 0.001$) for each experiment by unpaired *t* test.

20 The more rapid clearance of streptococci from air sacs resulted from more intense recruitment of PMNs. The total cell population, the percentage of Mac-1 positive granulocytes (Springer, G. et al., "Mac-1:macrophage differentiation antigen identified by monoclonal antibody," Eur. J. Immunol. 9:301-306 (1979)), and the percentage of Gr-1 positive PMN (Brummer, E. et al., "Immunological activation of polymorphonuclear neutrophils for fungal killing: studies with murine cells and blastomyces dermatitidis in vitro," J. Leuko. Bio. 36:505-520 (1984)) in air sacs were compared by single color FACS analysis. Clark, J. M., "A new method for quantitation of cell-mediated immunity in the mouse," J. Reticuloendothel. Soc. 25:255-267 (1979). Briefly, 25 in a FACS analysis, individual cells in suspension are labelled with specific fluorescent monoantibodies. Aliquots of labelled cells are injected into a FAC-

30

Scan flowcytometer or fluorescent cell sorter which counts cells based on their unique fluorescence.

Air sacs infected with the SCP⁻ deletion mutant contained twice as many inflammatory cells as those inoculated with SCP⁺ streptococci (Figure 4). A
5 hundred-fold increase in the inoculum size did not alter this difference. Air sacs infected with 1×10^6 SCP⁻ cells, strain MJ3-15, contained three times more Gr-1 positive cells than those inoculated with the SCP⁺ culture. In air sacs inoculated with SCP⁺ streptococci approximately 6% of the cells were PMNs and 21% were other kinds of Mac-1⁺ granulocytes, including PMNs. In contrast, air sacs
10 inoculated with SCP⁻ streptococci contained predominately PMNs. Gr-1 positive cells were equal to or greater than the number of Mac-1 positive cells. Flow cytometer gates were set to measure only high staining granulocytes. The remaining 70-80% of cells not stained with either antibody were likely either low staining granulocytes, red blood cells or lymphocytes. Large numbers of
15 lymphocytes were observed microscopically in Wrights stained air sac preparations.

SCP⁺ colonies of streptococci that emerged from spleen homogenates were highly encapsulated, resembling water drops. In contrast the few SCP⁻ colonies arising from lymph nodes, were more like the inoculum. They were
20 mixtures of non-mucoid and moderately mucoid colonies. These data suggest that M⁺SCP⁺ encapsulated streptococci can adapt, multiply and invade the bloodstream within 4 hours after infection. The basis for differential trafficking of mutant and wild-type streptococci may be due to the more vigorous influx of phagocytic cells in response to SCP⁻ bacteria. Macrophages and/or skin
25 dendritic cells may more rapidly engulfed SCP streptococci and delivered them to lymph nodes. Reduction of mutant streptococci relative to wild-type is an unexpected finding, because SCP⁻ streptococci are M⁺ and resistant to phagocytosis by human neutrophils in vitro.

EXAMPLE 3

30 SCP Is Required for Colonization of the Mouse Nasopharynx

Mice were inoculated intranasally to evaluate the relative capacity of wild-type (SCP⁺) and SCP⁻ streptococci to colonize the nasopharynx.

Streptomycin resistant M49 strain CS101 and deletion mutant MJ3-15 were used

in these experiments. Cultures were not mouse passed in order to avoid selection of variants that might be uniquely mouse virulent, but no longer depend on M protein and/or SCP for persistence in the animal.

Sixteen hour cultures of challenge streptococcal strains ($1 \times 10^8 - 9 \times 10^8$ CFU), grown in Todd-Hewitt broth containing 20% normal rabbit serum and resuspended in 10 μ l of PBS, were administered intranasally to 25g female CD1 (Charles River Breeding Laboratories, Inc., Wilmington, MA.) or BALB/c mice (Sasco, Omaha NE). Viable counts were determined by plating dilutions of cultures on blood agar plates. Throat swabs were taken daily from anesthetized mice for 6 to 10 days after inoculation and streaked onto blood agar plates containing 200ug/ml streptomycin. After overnight incubation at 37°C, the number of β -hemolytic colonies on plates were counted. All challenge strains were marked by streptomycin resistance to distinguish them from β -hemolytic bacteria which may be persist in the normal flora. Throat swabs were cultured on blood agar containing streptomycin. The presence of one β -hemolytic colony was taken as a positive culture.

CD1 outbred mice were intranasally inoculated with 2×10^8 stationary phase CFU. The nasopharynxes of anesthetized mice were swabbed daily for 8-10 days and streaked on blood agar containing streptomycin. Differences between SCP⁺ and SCP⁻ were evident by day 1, however, statistically significant differences were not observed until days 3 and 4 (Figure 5). By day four 9/18 mice infected with M⁺SCP⁺ streptococci produced positive throat cultures, whereas only 2/18 mice infected with M⁺SCP⁻ strain retained streptococci in their throats. Four of 18 mice died from infection with SCP⁺ streptococci. None of the mice following infection with SCP⁻ bacteria succumbed to the infection. The numbers of colonies on the blood agar plates were also consistent with more rapid clearance of SCP⁻ streptococci. For example, on the third day cultures from seven mice contained >100 SCP⁺ CFU, whereas, only one mouse inoculated SCP⁻ streptococci contained > 100 CFU.

Because M49 streptococci are more often associated with skin infections the above experiments were repeated with an M6 strain, a serotype more often associated with throat infections. An insertion mutant, strain AK1.4, was constructed using the M6 strain UAB200 and the strategy previously described

in Example 1. Strain AK1.4 was also cleared more rapidly than the wild-type M6 culture from the nasopharynx. (Figure 6) The above experiments confirm that group A streptococci are dependent upon SCP for persistence in the mouse nasopharynx. All SCP⁻ variants used in the above experiments were M⁺, i.e. they
 5 resisted phagocytosis by fresh human blood. Yet, they were cleared from the nasopharyngeal mucosa.

EXAMPLE 4

Intranasal Immunization of Mice with Purified Recombinant SCPA49 Blocks Colonization Following Intranasal Challenge

10 a) Construction of recombinant vaccine Δ SCPA49 encoding Thr⁶³ through His¹⁰³¹ (Figures 2 and 7).

A PCR fragment which corresponds to a truncated form of the *scpA49* gene was cloned from CS101 M49 group A streptococci (Δ SCPA49). This fragment was amplified by PCR using a forward primer beginning at nucleotide
 15 1033 and a reverse primer beginning at nucleotide 3941 (numbering corresponding to that of Chen, C., and Cleary, P., "Complete nucleotide sequence of the streptococcal C5a peptidase gene of *Streptococcus pyogenes*," *J. Biol. Chem.*, 265:3161-3167 (1990)). The fragment was ligated to the thrombin binding site of glutathione transferase gene on the pGex-4T-1 high expression
 20 vector from Pharmacia Inc. The plasmid containing the recombinant *scpA* fragment, designated pJC6, has been deposited in the American Type Culture Collection, Rockville, MD, under the provision of the Budapest Treaty, and assigned ATCC accession number 98225.

The Δ SCPA49, a 2908 bp fragment of *scpA49*, was amplified by PCR
 25 using an *scpA49* forward primer containing a *Bam*HI recognition sequence (5'-CCCCCGGATCCACCAAACCCACAAACTC-3') (SEQ ID NO:8) and an *scpA* reverse primer (5'-GAGTGGCCCTCCAATAGC-3') (SEQ ID NO:9). Sequences which code for the signal peptide and membrane anchor regions of the SCPA protein were deleted from the resulting PCR product. PCR products
 30 were digested with *Bam*HI and ligated to *Bam*HI and *Sma*I restriction sites in the thrombin recognition site of the glutathione S-transferase gene on the pGEX-4T-1 high expression vector from Pharmacia Inc. (Piscataway, NJ). The recombinant plasmid was transformed into *E.coli* DH5 α . The Δ SCPA49 fusion

protein from one transformant, *E. coli* (pJC6), was purified by affinity chromatography on a glutathione Sepharose 4B column. The transferase-SCP fusion protein from one *E. coli* clone was expressed and purified by affinity chromatography on a glutathione Sepharose 4b column. All methods are
5 described by the manufacturer (Pharmacia). The Δ SCPA49 was cleaved from the hybrid protein by thrombin digestion. The thrombin was removed from eluted SCP by chromatography on a benzamidine Sepharose 6B column (Pharmacia). Following digestion with thrombin, thrombin was removed by chromatography on a benzamidine-Sepharose 6B column. Methods of
10 expression and purification are described by the manufacturer. The affinity purified protein was confirmed to be pure Δ SCPA49 by SDS-PAGE and by Western blot. This affinity purified, truncated Δ SCPA49 protein lacked peptidase activity when tested by the PMN adherence assay (described in Example 1 above). Hyperimmune antiserum, directed against purified
15 Δ SCPA49 was prepared in rabbits.

b) Immunization and challenge protocol. Four week old, outbred, CD1 female mice were immunized by administration of 20 μ g of affinity purified Δ SCPA49 in 10 μ l PBS into each nostril. Mice were immunized 3 times on alternating days and boosted again three weeks after the third immunization.
20 After two weeks rest, mice were again boosted. D. Bessen et al., "Influence of Intranasal Immunization with Synthetic Peptides Corresponding to Conserved Epitopes of M Protein on Mucosal Colonization by Group A Streptococci," *Infect. Immun.*, 56, pp. 2666-2672 (1988). Control mice received only PBS. Prior to infection, all mice which were immunized with Δ SCPA49 protein were
25 determined by ELISA to have high titers of antibodies against Δ SCPA49 antigen in their serum and saliva. Group A streptococci, strain CS101 (2.0×10^8 CFU), CS210 (3.6×10^8 CFU), CS463 (7.8×10^8 CFU), 90-131 (3.4×10^8 CFU), and UAB200 (9.6×10^8 CFU) were used to intranasally challenge the mice 7 days after the last vaccine booster. Animal studies were performed according to
30 National Institutes of Health guidelines.

c) Sample collection and ELISA. Blood and saliva samples were collected from anesthetized mice after immunization. All sera were tested for the presence of SCPA49 antibodies by ELISA, as previously described. S.P.

O'Connor et al., "The Human Antibody Response to Streptococcal C5a Peptidase," *J. Infect. Dis.*, 163, pp. 109-116 (1990). Purified SCPA49 protein was bound to microtiter wells by addition of 500ng of purified protein in 0.05M bicarbonate buffer (pH 9.6). After overnight incubation at 4°C the wells were
5 washed, then blocked with 0.5% BSA in PBS for 1 hour. Salivation was stimulated in mice by injection of 100 µl of a 0.1% pilocarpine (Sigma) solution subcutaneously. Saliva samples were collected and spun at 14,000 rpm for 5 min in an Eppendorf microcentrifuge. The supernatants were tested for the presence of secretory IgA against ΔSCPA49 protein by ELISA. ELISA titers
10 represent the highest dilution of individual serum and saliva which had an OD₄₀₅ ≥ 0.1.

d) Evaluation of Antibody Response to ΔSCPA49

The immunogenicity of the subunit ΔSCPA49 vaccine was evaluated. Rabbits were immunized with purified ΔSCPA49. The rabbits developed high
15 levels of antibodies against ΔSCPA49 protein as determined by ELISA. Although the purified ΔSCPA49 immunogen lacked functional activity, hyperimmune rabbit antiserum could neutralize the peptidase activity of purified wild-type SCPA49 enzyme *in vitro*. Moreover, undiluted rabbit antiserum against ΔSCPA49 protein was able to neutralize C5a peptidase activity
20 associated with different serotypes (Figure 8). C5a peptidase activity associated with intact M1, M6 and M12 streptococci was inhibited by this antiserum, confirming that antibody against ΔSCPA49 protein lacks serotype specificity.

Also, serum and saliva samples were obtained from ten immunized and ten control mice to assess the immunogenicity of ΔSCPA49 protein when
25 administered via the intranasal route without adjuvants. Mice which were immunized with purified ΔSCPA49 protein developed high titers of ΔSCPA49-specific IgG in their sera, compared to control mice immunized with PBS (Figure 9). Titers of serum IgG directed against ΔSCPA49 ranged from 1:10,240 to 1:20,480. In contrast, ΔSCPA49-specific IgG titer of control mice
30 was not detectable in sera. Mice immunized with purified ΔSCPA49 protein also showed a significant increase in ΔSCPA49-specific salivary sIgA relative to control mice. Specific sIgA titers in saliva of immunized mice were greater than 1:16. In contrast, sIgA directed against ΔSCPA49 in the saliva of control mice

was not detectable. The relative concentration of IgG and sIgA in serum diluted 1/2560 and saliva diluted 1/2, respectively, are shown in Figure 9. These results demonstrate that purified Δ SCPA49 protein is an effective immunogen for the induction of specific systemic and secretory antibody responses in mice when
5 administered intranasally.

e) Impact of vaccine Δ SCPA49 on Clearance of Streptococci from Infected Mice.

Experiments were performed to determine whether immunization with the C5a peptidase would enhance clearance of streptococci from the
10 nasopharynx. Both hyperimmune rabbit and human sera that contain high levels of anti-SCPA antibody can neutralize SCPA activity *in vitro*. S.P. O'Connor et al., "The Human Antibody Response to Streptococcal C5a Peptidase," *J. Infect. Dis.*, 163, pp. 109-116 (1990). The fact that SCPA significantly facilitates
15 colonization of the oral mucosa suggests that immunization of mice with purified Δ SCPA49 could reduce the capacity of streptococci to colonize the nasopharynx. Mice were immunized intranasally with affinity purified, genetically inactivated SCPA to test this possibility. The truncated protein, Δ SCPA49, was
administered intranasally without adjuvants or carriers. Pharyngeal colonization of vaccinated mice by wild-type M⁺ SCPA⁺ streptococci differed significantly
20 from those immunized with PBS in three independent experiments using mice vaccinated with two different preparations of purified Δ SCPA49 protein (Tables 3 and 4; Figure 10). Only one of 13 mice immunized with Δ SCPA49 protein was culture positive for streptococci ten days after inoculation (Table 4; Figure
10). In contrast, 30-58% of the non-vaccinated controls remained culture
25 positive for six days, and some were still positive ten days after infection. The numbers of β -hemolytic, streptomycin resistant colonies on blood agar plates also showed a significant difference between Δ SCPA49 vaccinated and control mice. Different sets of immunized mice cleared serotype M49 streptococci significantly more rapidly from their nasopharynx than non-immunized control.

WO 00/34487

PCT/US99/28826

34

Table 3: Throat cultures for streptococci after intranasal challenge of mice vaccinated intranasally with PBS or SCP expressed in *E. coli* DH5 α (CFU after vaccine)

5	Mice	Days after challenge									
		1	2	3	4	5	6	7	8	9	10
10	PBSCT-II										
	1	0	0	0	0	0	0	0	0	0	0
	2	3	0	0	0	0	0	0	0	0	0
	3	77	>200	150	4	11	3	0	51	97	53
	4	9	>200	>200	3	11	3	0	0	0	0
	5	0	0	0	0	0	0	0	0	0	0
	6	4	6	45	47	3	>200	29	>200	83	70
	7	15	194	>200	9	172	10	5	3	0	0
	8	0	0	0	0	0	0	0	0	0	0
	9	0	32	4	4	0	0	0	0	0	0
	10	2	0	0	0	0	0	0	0	0	0
	11	3	0	0	0	0	0	0	0	0	0
	12	0	0	0	0	0	0	0	0	0	0
20	13	127	4	0	0	0	0	0	0	0	0
	No. of positive	8	6	5	5	4	4	2	3	2	2
30	SCPAD-II										
	1	0	0	0	0	0	0	0	0	0	0
	2	0	0	0	0	0	0	0	0	0	0
	3	0	0	0	0	0	0	0	0	0	0
	4	0	0	0	0	0	0	0	0	0	0
	5	35	0	0	0	0	0	0	0	0	0
	6	0	0	0	0	0	0	0	0	0	0
	7	0	0	0	0	0	0	0	0	0	0
	8	0	0	0	0	0	0	0	0	0	0
	9	0	0	0	0	0	0	0	0	0	0
	10	0	0	0	0	0	0	0	0	0	0
	11	0	0	0	21	0	0	0	0	0	0
	12	0	0	0	0	0	0	0	0	0	0
	13	0	0	0	0	0	0	0	0	0	0
	No. of positive	1	0	0	1	0	0	0	0	0	0

40

Table 4: Throat cultures for streptococci after intranasal challenge of mice vaccinated intranasally with PBS or SCP expressed in *E. coli* DH5 α (CFU after vaccine)

5	Mice*	Days after challenge									
		1	2	3	4	5	6	7	8	9	10
10	PBSCT-I										
	1	112	143	85	16	0	0	0	0	0	0
	2	127	27	18	89	3	7	7	7	70	3
	3	>200	>200	>200	>200	>200	>200	>200	108	>200	66
	4	31	200	4	2	0	0	0	0	0	0
	5	4	0	0	3	3	0	0	0	0	0
	6	0	0	0	0	0	0	0	0	0	0
	7	>200	>200	120	125	91	145	>200	>200	>200	166
	8	2	0	0	0	0	0	0	0	0	0
	9	0	0	0	0	0	0	0	0	0	0
	10	0	0	0	0	0	0	0	0	0	0
15	11	37	>200	194	16	>200	47	>200	101	>200	>200
	No. of positive										
	20	8	6	6	7	5	4	4	4	4	4
25	SCPAD-I										
	1	6	0	0	0	0	0	0	0	0	0
	2	105	41	0	0	0	0	0	0	0	0
	3	0	0	0	0	0	0	0	0	0	0
	4	2	0	0	0	0	0	0	0	0	0
	5	2	0	0	0	0	0	0	0	0	0
	6	9	0	11	0	0	0	0	0	0	0
	7	0	0	0	0	0	0	0	0	0	0
	8	26	0	0	0	0	0	0	0	0	0
	9	0	19	0	0	5	57	0	0	21	91
	10	0	0	0	0	0	0	0	0	0	0
30	11	7	0	0	0	0	0	0	0	0	0
	No. of positive										
	35	7	2	1	0	1	1	0	0	1	1

* Mice were inoculated twice, because the dose of bacteria was too low at first time inoculation.

Last, it was examined whether SCP of one serotype would vaccinate animals against infection from other serotypes. There are more than 80 different serotypes of group A streptococci. An effective vaccine should prevent infection to more than one streptococcal serotype. Cross-protection was produced against
5 colonization by the streptococcal OF⁺ serotypes M2 and M11 and the OF⁻ serotypes M1 and M6. The fact that rabbit serum directed against ΔSCPA49 protein from serotype M49 streptococci neutralized peptidase activity associated with several serotypes suggested that intranasal immunization with a single subunit vaccine might reduce or eliminate pharyngeal colonization by those
10 serotypes. To explore this possibility four groups of twenty mice were immunized by intranasal inoculation with affinity purified ΔSCPA49 protein as described above. Control mice received PBS. Prior to being challenged with streptococci, serum and saliva samples from randomly chosen, immunized and control mice were assayed for anti-SCPA antibody. All immunized mice tested
15 had developed a strong serum and measurable salivary antibody response. Pharyngeal colonization of mice immunized with ΔSCPA49 protein by strains of all four serotypes was reduced relative to non-immunized controls. Differences were most significant on days 3 and 5 after inoculation (Table 5).

Table 5. Immune protectivity is serotype independent

Day 3 after inoculation		Day 5 after inoculation			
Nonimmune		Immune		Nonimmune	
(+/total)	%	(+/total)	%	(+/total)	%
)					
M2	10/19	52.	2/19*	3/19	1/19
		6	10.	15.8	5.2
			5		
M11	17/20	85	11/20*	8/20	2/20*
			55	40	10
M1	16/19	84.	11/19	7/19	2/19*
		2	57.	37	10.
			9		5
M6	14/20	70	12/19	8/20	4/19
			63.	40	21.
			2		1

+ means culture positive mice. * Differences between immunized and non-immunized mice are statistically significant (P<0.05). P values were calculated by x² analysis.

Statistically significant differences were observed between immunized and control mice inoculated with serotype M2, M11 and M1 strains. However, the OF⁺ serotypes M2 and M11 were more efficiently eliminated by immunized mice than were the OF⁻ strains, M1 and M6. M1 streptococcal colonization of immunized mice was significantly reduced relative to control mice. Only 10.5% of the immunized mice were culture positive by day 5 post-infection. In contrast, 37% of the control mice were culture positive with this strain. Although immunized mice appeared to clear M6 streptococci more rapidly, the differences were not statistically significant. As in previous experiments the number of β -hemolytic streptococcal colonies on blood agar plates were significantly fewer in samples taken from vaccinated mice than those taken from control animals. Thus, the Δ SCPA 49 protein was an effective vaccine that provided cross-protection against other streptococcal serotypes.

EXAMPLE 5

15 Site-directed Mutagenesis of SCPA49

Group A streptococcal serotypes can be divided into two major groups, OF⁺ and OF⁻ strains. The latter are more often associated with rheumatic fever and toxic shock, whereas OF⁺ strains are a common cause of impetigo and acute glomerulonephritis. Although the SCPA proteins of these groups are 95-98% identical, it is possible that the immune response to them may be somewhat different. This concern prompted efforts to develop defined variant SCPAs from an M1 OF⁻ strain and from an M49 OF⁺ strain in parallel. Amino acids that are required for catalytic activity were replaced with those expected to inactivate the enzyme (Figure 1). The N and C-terminal amino acid boundaries of SCPA49, expressed the pGEX-4T-1 subclones, were Asn³² and His¹¹³⁹, respectively (Figures 1 and 8). Ser⁵¹² (SCPA49S512A), Asn²⁹⁵ (SCPA49N295A) and Asp¹³⁰ (SCPA49D130A) in the SCPA49 protein were replaced with Ala, and Asn²⁹⁵ (SCPA49N295R) was replaced by Arg (Deborah Stafslie, M.S. Thesis, University of Minnesota).

30 The method used to introduce mutations into the *scpA49* gene from Streptococcus strain CS101 was the "megaprimer" method of site-directed mutagenesis. Barik, S., "Site directed mutagenesis in vitro megaprimer PCR," In: Methods in Molecular Biology, Vol. 57: In Vitro Mutagenesis Protocols,

Humana Press, Inc. Totowa, NJ (1996). The serine mutation was introduced using primers *scpFor940* (5'-CCCCCGGATCCAATACTGTGACAGAAGACACTCC-3'), SEQ ID NO:10, and *scpmutrev1883* (5'-TTTCTGGAAGTAGTATGTCTGCGCC-3'), SEQ ID NO:11, to amplify a 1450 bp double-stranded PCR product. This first PCR product, a "megaprimer," was purified using the Qiagen Qiaquick Gel Extraction Kit, then used in a second asymmetrical PCR reaction to amplify the 3.3 kb *scpA49* gene containing the desired mutation. Five cycles of denaturation (93°C, 1 min) and extension (72°C, 5 min) were carried out before addition of the reverse primer *scpRev4263*, (3'-CCCCCCTCGAGATGTAAACGATTTGTATCCTTGTCATTAG-3') SEQ ID NO:12. During the fifth cycle at 72°C, the reverse primer was added at a concentration of 1 mM. The amplification was completed using 25 cycles at 94°C for 1 min, 58°C for 2 min, and 72°C for 2-3.5 minutes. Reactant concentrations were the same as described in the previous section, except that a forward primer was not added and the megaprimer was added at a concentration of 4-6 µg per 100 µl reaction. This process yielded variant protein SCPA49S512A (see Table 6 below).

The aspartate and asparagine variants were constructed in much the same fashion, using the reverse primers *scpmutrev717* (5'-CAGTGATTGATGCTGGTTTTGATAA-3') SEQ ID NO:13 and *scpmutrev1214* (5'-AGCTACTATCAGCACCAG-3') SEQ ID NO:14 to construct 311 bp and 805 bp megaprimers, respectively. The primer *scpmutrev717* was used to generate variant protein SCPA49D130A, and primer *scpmutrev1214* was used to generate variant protein SCPA49N295A (see Table 6 below). After Qiaquick purification, however, the megaprimer was treated with 0.1 U mung bean nuclease (per 4 µg DNA) and incubated at 30°C for 10 minutes. The nuclease was removed by phenol/chloroform extraction, and the megaprimer recovered in the aqueous phase by ethanol precipitation. The pellet was resuspended in 80 µl sterile double distilled water, and 37 µl of this was used in each 100 µl asymmetrical PCR reaction. The mutated gene was then cloned into pGEX 4T-1 as previously described. Sequencing of variants was performed using ³⁵S-labeled dATP and the Sequenase kit (Stratagene) or using

Table 6: Amino acid sequence comparison of variant proteins

		127	132	291	297	508	514	876	883
5	Wild-type SCPA49	AVIDAG		TSAGNDS		LSGTSGT		STLGSRF	
	SCP S512A49	AVIDAG		TSAGNDS		LSGTAGT		STLGSRF	
	SCP D130A49	AVIAAG		TSAGNDS		LSGTSGT		STLGSRF	
	SCP N295A49	AVIDAG		TSAGADS		LSGTSGT		STLGSRF	

10 The *E. coli* expression vector pGEX 4T-1 was used to overexpress variant SCPA as GST fusion proteins. Recombinant SCPA was purified according to the protocol provided in the GST Gene Fusion System Handbook (Pharmacia) previous to this work. The SCPA protein antigen was purified by affinity chromatography as described above.

Construction of SCPA1 and SCPB Variants

The wild-type *scpA1* gene was amplified by PCR from M1 serotype of *S. pyogenes* (strain 90-226) in the following manner. Primers were designed such that only a fragment of the complete gene would be expressed. This fragment corresponds to the start of the mature protein and terminates just before the cell wall associated domain residue Asn³² through Asp¹⁰³⁸ (Figure 2). The forward primer 5' - CCCCCCGAATTCATTACTGTG ACAGAAGACACTCCTGC - 3' (SEQ ID NO:15) anneals starting at base number 940 (numbering corresponding to that of Chen, C., and Cleary, P., "Complete nucleotide sequence of the streptococcal C5a peptidase gene of *Streptococcus pyogenes*," *J. Biol. Chem.*, 265:3161-3167 (1990). The opposing, reverse PCR primer, 5' - CCCCCCGGATCCTTATTGTTCTGGTTTATTAGA GTGGCC - 3' (SEQ ID NO:16) anneals at base number 3954 just upstream of a region of DNA repeats. This repeat region of the protein is predicted to be the part that passes through, and then attaches to the peptidoglycan of the cell wall. The italicized region of each primer is additional sequence that has been added to the *S. pyogenes* sequence to enable the cloning process. The underlined region of the forward primer incorporates a *EcoRI* restriction site, the underlined portion of the reverse primer a *BamHI* site. The reverse primer also incorporates a stop codon (TAA) in frame of the gene that terminates translation.

The resultant PCR product corresponding to bases 940-3954 was cloned into an intermediate vector pCR2.1 (Invitrogen, Inc.) and transformed into *E. coli* Top10F cells (Invitrogen, Inc.). Plasmid DNA from an appropriate transformant was restricted with *EcoRI* and *BamHI*. The 3018 base fragment, containing the fragment of *scpA1*, was gel purified following standard procedures and ligated into the expression vector pTrc99a (Pharmacia) restricted with the same enzymes. This ligation was transformed into *E. coli* DH5 α cells and a transformant was selected that contained the desired plasmid construction. The resultant plasmid places the PCR fragment of *scpA1* behind a Shine-Dalgarno sequence and ATG start site, and is under the transcriptional control of the *trc* Promoter, that is inducible with the allolactose analogue IPTG.

Site-specific genetic variants of the wild-type *scpA1* were constructed following a procedure described by C. L. Fisher and G. K. Pei, "Modification of a PCR-based site-directed mutagenesis method," *BioTechniques*, 23:570-574 (1997). The appropriate amino acid residues within SCPA1 important for protease activity were predicted by sequence comparisons to the family of subtilisin-like serine proteases. Siezen, R. J., et al., "Homology modeling and protein engineering strategy of subtilases, the family of subtilisin-like serine proteinases," *Protein Engineering*, 4:719-737 (1991); Chen, C., and Cleary, P., "Complete nucleotide sequence of the streptococcal C5a peptidase gene of *Streptococcus pyogenes*," *J. Biol. Chem.*, 265:3161-3167 (1990). Three residues, conserved amongst this family, are involved in the formation of the active site. In SCPA1, these correspond to the Asp¹³⁰, His¹⁹³, and Ser⁵¹². Three sets of non-overlapping oligonucleotides were designed for use in PCR to alter each one of these amino acid residues. These oligonucleotides were designed to amplify away from each other on opposite strands of DNA. In each set, the 5' end of one of the primers would contain the codon encoding one of these amino acids for mutation and this codon would be altered to encode an alanine. These three sets of primers are listed below; the codons that are changes are italicized.

30 D130A:

Forward (SEQ ID NO:17)

5' - ATT GCT GCT GGT TTT GAT AAA AAT CAT GAA GCG - 3'

GAT codon change to GCT corresponds to an aspartate to alanine amino acid change.

Reverse (SEQ ID NO:18)

5' - CAC TGC AAC AAC AGT CCC - 3'

5 **H193A:**

Forward (SEQ ID NO:19)

5' - GAG GCC GGC ACA CAC GTG - 3'

CAC codon change to GCC corresponds to a histidine to alanine amino acid change.

10 Reverse (SEQ ID NO:20)

5' - TTG ATC GAC AGC GGT TTT ACC - 3'

S512A:

Forward (SEQ ID NO:21)

5' - ACT GCT ATG TCT GCT CCA TTA G -3'

15 ACT codon change to GCT corresponds to a serine to alanine amino acid change.

Reverse (SEQ ID NO:22)

5' - TCC AGA AAG TTT GGC ATA CTT GTT GTT AGC C

20 These sets of PCR primers were used in three separate reactions. The template DNA was pLP605, which contained the wild-type *scpA1* sequence. The PCR products were subsequently self-ligated and transformed into the *E. coli* strain Top10F' (Invitrogen, Inc.). Transformants were screened for the appropriate size and restriction pattern. The sequence change in the S512A
25 variant destroys a unique *SpeI* restriction site so that this mutation could be identified directly by restriction analysis. All potential variants were confirmed by DNA sequencing. Subsequently, the D130A mutation was combined with the S512A mutation to form a double variant utilizing a unique *PstI* site between these two regions of the protein. The final alteration was to change the antibiotic
30 selection from ampicillin to kanamycin by moving the variant *scpA1* genes to a previously altered pTRC99a vector (Pharmacia, Inc.) containing the kanamycin gene.

A variant of SCPB protein was constructed using the method described above for SCPA1 mutants. The wild-type SCPB gene was cloned from group B streptococcus 78-471 (Type IIa⁺).

EXAMPLE 7

5

Analysis of Variant Proteins

Proteins expressed from each of the variant constructs were analyzed by SDS polyacrylamide gel electrophoresis. The expected size of the protein is 121 kD, however, the proline-rich cell wall spanning domain at the carboxy terminus of the enzyme causes the protein to run slightly slower during SDS-PAGE. Therefore the apparent molecular weight is 130 kD when determined by SDS-PAGE. Since active SCP could be harmful to the host, it was important that the variant proteins lacked enzymatic activity. Two properties of the variant proteins were evaluated. The specific activities of the wild-type and variant proteins as determined by PMN adherence assay are compared in Table 7. These experiments indicated that the substituted amino acids reduced enzymatic activity by greater than 90%.

Table 7: PMN adherence assay determination of variant protease activity

	Protein	Activity (U/mg*10 ⁻³)
	Wild-type	170
20	SCPA49D130A	<20
	SCPA49N295A	<20
	SCPA49S512A	<20

The variant proteins were also compared to the wild-type protein for their capacity to bind antibody directed against the wild-type enzyme. Competitive ELISA assays were used for this purpose. Competitive ELISAs measured the inhibition of antibody binding to immobilized antigen by soluble antigen. A constant amount of wild-type antigen was bound to wells of the microtiter plate. A constant amount of antibody is added at the same time with varying amounts of soluble competitive antigen. The slope of the percent inhibition versus antigen concentration curves estimate the relative binding affinity of the soluble antigen for antibody. While the binding constants cannot be calculated without knowing the exact concentration of anti-SCPA in the antiserum, the relative binding affinities of several proteins were compared (Figure 11). Since the

slopes of the percent inhibition versus concentration curves are the same for the wild-type and variant proteins, it was concluded that amino acid substitution did not alter the ability of antibody to bind to the variant proteins.

Recombinant SCPA1, SCPA49 and SCPB proteins were also determined
5 to bind equally well to anti-SCP antibody (Figure 12). In this experiment the plate antigen was SCPA49 and the antibody was rabbit anti-SCPA49. The relative affinities of this antibody for these antigens, indicated by the slope of the curves is highly similar. These results demonstrate that SCPA protein from M49 OF⁺ and M1 OF⁻ group A Streptococci, and from group B streptococci are
10 equivalent with regard to antibody recognition and may be used interchangeably in a vaccine preparation.

EXAMPLE 8

Subcutaneous (SQ) Administration of SCPA Antigen

Induces Protection in Mice

15 All earlier protection studies were performed by administering affinity purified SCPA49 protein intranasally without adjuvant. Intramuscular or SQ injection of antigens is historically a preferred, more accepted method of vaccine delivery. Therefore, experiments were performed to test whether SQ injections of SCPA with MPL/alum induced a protective immune response and whether
20 that response reduced colonization when the challenge strain of group A streptococcus differed in serotype from the source of the SCPA vaccine. The capacity of immunized mice to clear streptococci from the oral-nasal pharyngeal mucosa was evaluated by throat culture or by sampling dissected nasal tissue. Representative throat culture data are presented in Table 8.

Table 8: Subcutaneous vaccination of mice

	Vaccine ^a	Challenge Bacteria ^b	Percent Colonized ^c	
			Control Mice	SCPA-Immunized Mice
5	SCPA49S512A	OF ⁺ M49	64% (3)	36%
	ΔSCPA49	OF ⁺ M49	64% (3)	20%
	ΔSCPA49	OF ⁻ M1	33% (5)	8%
	SCPA1S512A	OF ⁻ M49	23% (5)	8%

- 10 ^a Vaccines contained 10 μg of the indicated antigens mixed with adjuvants MPL and alum. Experimental groups each contained 13-20 mice. Control mice were immunized with tetanus toxoid mixed with the same adjuvant.
- ^b Mice were infected by intranasal inoculation.
- ^c Colonization was assessed by throat culture. The numbers in parentheses indicate the
- 15 day on which the cultures were taken.

Mice immunized by SQ injection of each of the three different forms of SCPA antigen induced moderate protection. Immunization with ΔSCPA49 protected against both OF⁻ M1 and OF⁺ M49 strains. SCPA49S512A and

20 SCPA1S512A were chosen for subsequent study.

Persistence of streptococci following intranasal challenge was also assessed by a more quantitative assay. This method involved sacrificing groups of mice at different times following infection, and dissecting nasal tissue (NT), which was then assayed for viable streptococci (CFU). Standard amounts of NT

25 were homogenized in buffer and the number of CFU/mg tissue was determined by viable count.

Three groups of mice were immunized SQ with SCPA49S512A, SCPA1S512A or tetanus toxoid. All vaccines were mixed with MPL/Alum adjuvants as before. Mice received four injections of 5 μg protein antigen and

30 then challenged two weeks after the last injection. Nasal tissue was harvested 16 hours after challenge with the OF⁺ M49 strain CS101. The geometric means of CFU/mg tissue are shown in Table 9.

Table 9: Geometric means of CFU/mg nasal tissue

	Vaccine Antigen	16 hours ^a
	Tetanus	5.71 ^b
	SCPA49S512A	2.27
5	SCPA1S512A	1.60

^a The time at which NT was taken following intranasal infection of mice.

^b Values are log values.

10 The number of streptococci associated with nasal tissue decreased with
time, as expected and the decrease was more rapid and complete in mice
immunized with SCPA antigen. All groups of mice that had been immunized
with SCPA retained fewer streptococci than control mice. In this experiment
immunization with SCPA1S512A was most effective and induced a cross-
15 protective response, since the challenge strain CS101 is OF⁺ M49 and the source
of vaccine protein SCPA1S512A from an OF⁻ M1 strain. These results confirm
that a single SCPA antigen can induce protection against heterologous serotypes.
Protection is afforded by antibody that neutralizes peptidase activity on the
bacterial surface. This increases the influx of phagocytes within a few hours
20 from the time streptococci are deposited on mucosal tissue. Rapid clearance of
streptococci by phagocytes is presumed to prevent subsequent multiplication and
persistence of the bacteria. Mice uniformly had serum IgG titers of 1:32,000 or
greater when assayed by ELISA, indicating that SQ injection of SCPA antigen
with adjuvant consistently induced a vigorous antibody response.

25

EXAMPLE 9

**C5a Peptidase from Group B Streptococci Is Nearly Identical in Sequence
to Those from M12 and M49 Group A Streptococci**

The group B streptococci C5a peptidase (SCPB) gene was cloned,
sequenced and compared to that from serotype group A streptococci M12 and
30 M49. The entire *scpB* gene was amplified by PCR using primers which
correspond to portions of the *scpA12* sequence using the method described
above. The SCPB gene encodes an open reading frame (ORF) of 3450 bp which
specifies a protein of 1150 amino acids with Mr of 126,237 da. The amino acid
sequence of SCPB is shown in Figure 2. Comparison of the *scpB* nucleotide and
35 deduced amino acid sequence to those from M12 and M49 group A streptococci

showed high similarities, 98% and 97%, respectively. *ScpB* contained a 50 bp deletion which overlapped two of the C-terminal repeats, and had several other minor differences relative to *scpA* genes. Alignment of the sequences showed that *scpA12* is actually phylogenetically closer to *scpB* than it is to *scpA49*.

- 5 Thirty strains, representing serotypes III, III/R, II, Ia/c, NT/c, NT/c/R1 carry a copy of *scpB*.

Recombinant SCP was expressed in *E. coli* using expression vector plasmid pGEX-4T-1 (ATCC accession number 98225) and was shown to be identical to the enzyme extracted from the parental group B streptococcal strain
10 78-471 (Type II a+ b). Western blot analysis suggested the recombinant SCP is identical to the C5ase enzyme previously purified from group B streptococci.

The

invention has been described with reference to various specific and preferred
15 embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the scope of the invention.

WO 00/34487

PCT/US99/28826

1

SEQUENCE LISTING

<110> Regents of the University of Minnesota et al.

5

<120> Streptococcal C5a peptidase vaccine

<130> 600.450WO1

10

<150> US 09/206,898

<151> 1998-12-07

<150> US 08/589,756

<151> 1996-01-22

15

<160> 23

<170> FastSEQ for Windows Version 3.0

20

<210> 1

<211> 1164

<212> PRT

<213> Streptococcus pyogenes

25

<400> 1

Leu Arg Lys Lys Gln Lys Leu Pro Phe Asp Lys Leu Ala Ile Ala Leu

1

5

10

15

Met Ser Thr Ser Ile Leu Leu Asn Ala Gln Ser Asp Ile Lys Ala Asn

20

25

30

30 Thr Val Thr Glu Asp Thr Pro Ala Thr Glu Gln Ala Val Glu Thr Pro

35

40

45

Gln Pro Thr Thr Val Ser Glu Glu Val Pro Ser Ser Lys Glu Thr Lys

50

55

60

Thr Pro Gln Thr Pro Asp Asp Ala Glu Glu Thr Val Ala Asp Asp Ala

35 65

70

75

80

Asn Asp Leu Ala Pro Gln Ala Pro Ala Lys Thr Pro Asp Thr Ser Ala

85

90

95

Thr Ser Lys Ala Thr Ile Arg Asp Leu Asn Asp Pro Ser Gln Val Lys

100

105

110

40 Thr Leu Gln Glu Lys Ala Gly Lys Gly Ala Gly Thr Val Val Ala Val

115

120

125

WO 00/34487

PCT/US99/28826

2

Ile Asp Ala Gly Phe Asp Lys Asn His Glu Ala Trp Arg Leu Thr Asp
 130 135 140
 Lys Ala Lys Ala Arg Tyr Gln Ser Lys Glu Asp Leu Glu Lys Ala Lys
 145 150 155 160
 5 Lys Glu His Gly Ile Thr Tyr Gly Glu Trp Val Asn Asp Lys Val Ala
 165 170 175
 Tyr Tyr His Asp Tyr Ser Lys Asp Gly Lys Thr Ala Val Asp Gln Glu
 180 185 190
 His Gly Thr His Val Ser Gly Ile Leu Ser Gly Asn Ala Pro Ser Glu
 10 195 200 205
 Thr Lys Glu Pro Tyr Arg Leu Glu Gly Ala Met Pro Glu Ala Gln Leu
 210 215 220
 Leu Leu Met Arg Val Glu Ile Val Asn Gly Leu Ala Asp Tyr Ala Arg
 225 230 235 240
 15 Asn Tyr Ala Gln Ala Ile Arg Asp Ala Val Asn Leu Gly Ala Lys Val
 245 250 255
 Ile Asn Met Ser Phe Gly Asn Ala Ala Leu Ala Tyr Ala Asn Leu Pro
 260 265 270
 Asp Glu Thr Lys Lys Pro Phe Val Tyr Ala Lys Ser Lys Gly Val Arg
 20 275 280 285
 Ile Val Thr Thr Ala Gly Asn Asp Ser Ser Phe Gly Gly Lys Thr Arg
 290 295 300
 Leu Pro Leu Ala Asp His Pro Asp Tyr Gly Val Val Gly Thr Pro Ala
 305 310 315 320
 25 Ala Ala Asp Ser Thr Leu Thr Val Ala Ser Tyr Ser Pro Asp Asn Gln
 325 330 335
 Leu Thr Glu Thr Ala Met Val Lys Thr Asp Asp Gln Gln Asp Lys Glu
 340 345 350
 Met Pro Val Leu Ser Thr Asn Arg Phe Glu Pro Asn Lys Ala Tyr Asp
 30 355 360 365
 Tyr Ala Tyr Ala Asn Arg Gly Met Lys Glu Asp Asp Phe Lys Asp Val
 370 375 380
 Lys Gly Lys Ile Ala Leu Ile Glu Arg Ser Asp Ile Asp Phe Thr Asp
 385 390 395 400
 35 Lys Ile Ala Asn Ala Lys Lys Ala Gly Ala Val Gly Val Leu Ile Tyr
 405 410 415
 Asp Asn Gln Asp Lys Gly Phe Pro Ile Glu Leu Pro Asn Val Asp Gln
 420 425 430
 Met Pro Ala Ala Phe Ile Ser Arg Lys Asp Gly Leu Leu Leu Lys Asp
 40 435 440 445

WO 00/34487

PCT/US99/28826

3

Asn Ser Gln Lys Thr Ile Thr Phe Asn Ala Thr Pro Lys Val Leu Pro
 450 455 460
 Thr Ala Ser Gly Thr Lys Leu Ser Arg Phe Ser Ser Trp Gly Leu Thr
 465 470 475 480
 5 Ala Asp Gly Asn Ile Lys Pro Asp Ile Ala Ala Pro Gly Gln Asp Ile
 485 490 495
 Leu Ser Ser Ala Ala Asn Asn Lys Tyr Ala Lys Leu Ser Gly Thr Ser
 500 505 510
 Met Ser Ala Pro Leu Val Ala Val Ile Met Gly Leu Leu Gln Lys Gln
 10 515 520 525
 Tyr Glu Thr Gln Tyr Pro Asp Met Thr Gln Ser Glu Arg Leu Asp Leu
 530 535 540
 Ala Lys Lys Val Leu Met Ser Ser Ala Thr Ala Leu Tyr Asp Glu Asp
 545 550 555 560
 15 Glu Lys Ala Tyr Phe Ser Pro Arg Gln Gln Gly Ala Gly Ala Val Asp
 565 570 575
 Ala Lys Lys Ala Ser Glu Ala Thr Met Tyr Val Thr Asp Lys Asp Asn
 580 585 590
 Thr Ser Ser Lys Val His Leu Asn Asn Val Ser Asp Lys Phe Glu Val
 20 595 600 605
 Thr Val Thr Val His Asn Lys Ser Asp Lys Pro His Glu Leu Tyr Tyr
 610 615 620
 Gln Ala Thr Val Gln Thr Asp Lys Val Asp Gly Lys His Phe Ala Leu
 625 630 635 640
 25 Ala Pro Lys Ala Leu Ile Glu Thr Ser Trp Gln Lys Ile Thr Ile Pro
 645 650 655
 Ala Asn Ser Ser Lys Gln Val Thr Ile Pro Ile Asp Ile Ser Gln Phe
 660 665 670
 Ser Lys Asp Leu Leu Ala Gln Met Lys Asn Gly Tyr Phe Leu Glu Gly
 30 675 680 685
 Phe Val Arg Ile Lys Gln Asp Pro Thr Lys Glu Glu Leu Met Ser Ile
 690 695 700
 Pro Tyr Ile Gly Phe Arg Gly Asp Phe Gly Asn Leu Ser Ala Leu Glu
 705 710 715 720
 35 Lys Pro Leu Tyr Asp Ser Lys Asp Gly Ser Ser Tyr Tyr His Glu Glu
 725 730 735
 Ile Ser Asp Ala Lys Asp Gln Leu Asp Gly Asp Gly Leu Gln Phe Tyr
 740 745 750
 Ala Leu Lys Asn Asp Phe Thr Ala Leu Thr Thr Glu Ser Asn Pro Trp
 40 755 760 765

WO 00/34487

PCT/US99/28826

4

Thr Ile Ile Asn Val Val Lys Glu Gly Val Glu Asn Ile Glu Asp Ile
 770 775 780
 Glu Ser Ser Glu Ile Thr Glu Thr Ile Phe Ala Gly Thr Phe Ala Lys
 785 790 795 800
 5 Gln Asp Asp Asp Arg His Tyr Tyr Ile His Arg His Ala Asn Gly Lys
 805 810 815
 Pro Tyr Ala Ala Ile Ser Pro Asn Gly Asp Gly Asn Arg Asp Tyr Val
 820 825 830
 Gln Phe His Gly Thr Phe Leu Arg Asn Ala Lys Asn Leu Val Ala Glu
 10 835 840 845
 Val Leu Asp Lys Glu Gly Asn Val Val Trp Thr Ser Glu Val Thr Glu
 850 855 860
 Gln Val Val Lys Asn Tyr Asn Asn Asp Leu Ala Ser Thr Leu Gly Ser
 865 870 875 880
 15 Thr Arg Phe Glu Ile Ser Arg Trp Asp Gly Lys Asp Lys Asp Ala Lys
 885 890 895
 Val Val Ala Asn Gly Thr Tyr Thr Tyr Arg Val Arg Tyr Thr Pro Ile
 900 905 910
 Ser Ser Gly Ala Lys Glu Gln His Thr Asp Phe Asp Val Ile Val Asp
 20 915 920 925
 Asn Thr Thr Pro Glu Val Ala Thr Ser Ala Thr Phe Ser Thr Glu Asp
 930 935 940
 Arg Arg Leu Thr Leu Ala Ser Lys Pro Gln Thr Ser Gln Pro Val Tyr
 945 950 955 960
 25 Arg Glu Arg Ile Ala Tyr Thr Tyr Met Asp Glu Asp Leu Pro Thr Thr
 965 970 975
 Glu Tyr Ile Ser Pro Asn Glu Asp Gly Thr Phe Thr Leu Pro Glu Glu
 980 985 990
 Ala Glu Thr Met Glu Gly Ala Thr Val Pro Leu Lys Met Ser Asp Phe
 30 995 1000 1005
 Thr Tyr Val Val Glu Asp Met Ala Gly Asn Ile Thr Tyr Thr Pro Val
 1010 1015 1020
 Thr Lys Leu Leu Glu Gly His Ser Asn Lys Pro Glu Gln Asp Gly Ser
 1025 1030 1035 1040
 35 Asp Gln Ala Pro Asp Lys Lys Pro Glu Thr Lys Pro Glu Gln Asp Gly
 1045 1050 1055
 Ser Asp Gln Ala Pro Asp Lys Lys Pro Glu Thr Lys Pro Gly Gln Asp
 1060 1065 1070
 Gly Ser Gly Gln Thr Pro Asp Lys Lys Pro Glu Thr Lys Pro Glu Lys
 40 1075 1080 1085

WO 00/34487

PCT/US99/28826

5

Asp Ser Ser Gly Gln Thr Pro Gly Lys Thr Pro Gln Lys Gly Gln Pro
 1090 1095 1100
 Ser Arg Thr Leu Glu Lys Arg Ser Ser Lys Arg Ala Leu Ala Thr Lys
 1105 1110 1115 1120
 5 Ala Ser Thr Arg Asp Gln Leu Pro Thr Thr Asn Asp Lys Asp Thr Asn
 1125 1130 1135
 Arg Leu His Leu Leu Lys Leu Val Met Thr Thr Phe Phe Leu Gly Leu
 1140 1145 1150
 Val Ala His Ile Phe Lys Thr Lys Arg Thr Glu Asp
 10 1155 1160

<210> 2

<211> 1167

<212> PRT

15 <213> Streptococcus pyogenes

<400> 2

Leu Arg Lys Lys Gln Lys Leu Pro Phe Asp Lys Leu Ala Ile Ala Leu
 1 5 10 15
 20 Met Ser Thr Ser Ile Leu Leu Asn Ala Gln Ser Asp Ile Lys Ala Asn
 20 25 30
 Thr Val Thr Glu Asp Thr Pro Val Thr Glu Gln Ala Val Glu Thr Pro
 35 40 45
 Gln Pro Thr Ala Val Ser Glu Glu Val Pro Ser Ser Lys Glu Thr Lys
 25 50 55 60
 Thr Pro Gln Thr Pro Asp Asp Ala Glu Glu Thr Ile Ala Asp Asp Ala
 65 70 75 80
 Asn Asp Leu Ala Pro Gln Ala Pro Ala Lys Thr Ala Asp Thr Pro Ala
 85 90 95
 30 Thr Ser Lys Ala Thr Ile Arg Asp Leu Asn Asp Pro Ser Gln Val Lys
 100 105 110
 Thr Leu Gln Glu Lys Ala Gly Lys Gly Ala Gly Thr Val Val Ala Val
 115 120 125
 Ile Asp Ala Gly Phe Asp Lys Asn His Glu Ala Trp Arg Leu Thr Asp
 35 130 135 140
 Lys Thr Lys Ala Arg Tyr Gln Ser Lys Glu Asp Leu Glu Lys Ala Lys
 145 150 155 160
 Lys Glu His Gly Ile Thr Tyr Gly Glu Trp Val Asn Asp Lys Val Ala
 165 170 175
 40 Tyr Tyr His Asp Tyr Ser Lys Asp Gly Lys Thr Ala Val Asp Gln Glu

WO 00/34487

PCT/US99/28826

6

		180		185		190			
		His Gly Thr	His Val Ser Gly Ile Leu Ser Gly Asn Ala Pro Ser Glu						
		195		200		205			
		Thr Lys Glu Pro Tyr Arg Leu Glu Gly Ala Met Pro Glu Ala Gln Leu							
5		210		215		220			
		Leu Leu Met Arg Val Glu Ile Val Asn Gly Leu Ala Asp Tyr Ala Arg							
		225		230		235			240
		Asn Tyr Ala Gln Ala Ile Arg Asp Ala Val Asn Leu Gly Ala Lys Val							
			245		250			255	
10		Ile Asn Met Ser Phe Gly Asn Ala Ala Leu Ala Tyr Ala Asn Leu Pro							
			260		265			270	
		Asp Glu Thr Lys Lys Ala Phe Asp Tyr Ala Lys Ser Lys Gly Val Ser							
			275		280			285	
		Ile Val Thr Ser Ala Gly Asn Asp Ser Ser Phe Gly Gly Lys Thr Arg							
15		290		295		300			
		Leu Pro Leu Ala Asp His Pro Asp Tyr Gly Val Val Gly Thr Pro Ala							
		305		310		315			320
		Ala Ala Asp Ser Thr Leu Thr Val Ala Ser Tyr Ser Pro Asp Lys Gln							
			325		330			335	
20		Leu Thr Glu Thr Ala Met Val Lys Thr Asp Asp Gln Gln Asp Lys Glu							
			340		345			350	
		Met Pro Val Leu Ser Thr Asn Arg Phe Glu Pro Asn Lys Ala Tyr Asp							
			355		360			365	
		Tyr Ala Tyr Ala Asn Arg Gly Met Lys Glu Asp Asp Phe Lys Asp Val							
25		370		375		380			
		Lys Gly Lys Ile Ala Leu Ile Glu Arg Gly Asp Ile Asp Phe Lys Asp							
		385		390		395			400
		Lys Val Ala Asn Ala Lys Lys Ala Gly Ala Val Gly Val Leu Ile Tyr							
			405		410			415	
30		Asp Asn Gln Asp Lys Gly Phe Pro Ile Glu Leu Pro Asn Val Asp Gln							
			420		425			430	
		Met Pro Ala Ala Phe Ile Ser Arg Lys Asp Gly Leu Leu Leu Lys Asp							
			435		440			445	
		Asn Pro Gln Lys Thr Ile Thr Phe Asn Ala Thr Pro Lys Val Leu Pro							
35		450		455		460			
		Thr Ala Ser Gly Thr Lys Leu Ser Arg Phe Ser Ser Trp Gly Leu Thr							
		465		470		475			480
		Ala Asp Gly Asn Ile Lys Pro Asp Ile Ala Ala Pro Gly Gln Asp Ile							
			485		490			495	
40		Leu Ser Ser Val Ala Asn Asn Lys Tyr Ala Lys Leu Ser Gly Thr Ser							

WO 00/34487

PCT/US99/28826

7

	500		505		510
	Met Ser Ala Pro Leu Val Ala Gly Ile Met Gly Leu Leu Gln Lys Gln				
	515		520		525
	Tyr Glu Thr Gln Tyr Pro Asp Met Thr Pro Ser Glu Arg Leu Asp Leu				
5	530		535		540
	Ala Lys Lys Val Leu Met Ser Ser Ala Thr Ala Leu Tyr Asp Glu Asp				
	545		550		555
	Glu Lys Ala Tyr Phe Ser Pro Arg Gln Gln Gly Ala Gly Ala Val Asp				
	565		570		575
10	Ala Lys Lys Ala Ser Ala Ala Thr Met Tyr Val Thr Asp Lys Asp Asn				
	580		585		590
	Thr Ser Ser Lys Val His Leu Asn Asn Val Ser Asp Lys Phe Glu Val				
	595		600		605
	Thr Val Thr Val His Asn Lys Ser Asp Lys Pro Gln Glu Leu Tyr Tyr				
15	610		615		620
	Gln Ala Thr Val Gln Thr Asp Lys Val Asp Gly Lys His Phe Ala Leu				
	625		630		635
	Ala Pro Lys Val Leu Tyr Glu Ala Ser Trp Gln Lys Ile Thr Ile Pro				
	645		650		655
20	Ala Asn Ser Ser Lys Gln Val Thr Val Pro Ile Asp Ala Ser Arg Phe				
	660		665		670
	Ser Lys Asp Leu Leu Ala Gln Met Lys Asn Gly Tyr Phe Leu Glu Gly				
	675		680		685
	Phe Val Arg Phe Lys Gln Asp Pro Thr Lys Glu Glu Leu Met Ser Ile				
25	690		695		700
	Pro Tyr Ile Gly Phe Arg Gly Asp Phe Gly Asn Leu Ser Ala Val Glu				
	705		710		715
	Lys Pro Ile Tyr Asp Ser Lys Asp Gly Ser Ser Tyr Tyr His Glu Ala				
	725		730		735
30	Asn Ser Asp Ala Lys Asp Gln Leu Asp Gly Asp Gly Leu Gln Phe Tyr				
	740		745		750
	Ala Leu Lys Asn Asn Phe Thr Ala Leu Thr Thr Glu Ser Asn Pro Trp				
	755		760		765
	Thr Ile Ile Lys Ala Val Lys Glu Gly Val Glu Asn Ile Glu Asp Ile				
35	770		775		780
	Glu Ser Ser Glu Ile Thr Glu Thr Ile Phe Ala Gly Thr Phe Ala Lys				
	785		790		795
	Gln Asp Asp Asp Ser His Tyr Tyr Ile His Arg His Ala Asn Gly Glu				
	805		810		815
40	Pro Tyr Ala Ala Ile Ser Pro Asn Gly Asp Gly Asn Arg Asp Tyr Val				

WO 00/34487

PCT/US99/28826

8

	820	825	830
	Gln Phe Gln Gly Thr Phe Leu Arg Asn Ala Lys Asn Leu Val Ala Glu		
	835	840	845
	Val Leu Asp Lys Glu Gly Asn Val Val Trp Thr Ser Glu Val Thr Glu		
5	850	855	860
	Gln Val Val Lys Asn Tyr Asn Asn Asp Leu Ala Ser Thr Leu Gly Ser		
	865	870	875 880
	Thr Arg Phe Glu Lys Thr Arg Trp Asp Gly Lys Asp Lys Asp Gly Lys		
	885	890	895
10	Val Val Ala Asn Gly Thr Tyr Thr Tyr Arg Val Arg Tyr Thr Pro Ile		
	900	905	910
	Ser Ser Gly Ala Lys Glu Gln His Thr Asp Phe Asp Val Ile Val Asp		
	915	920	925
	Asn Thr Thr Pro Glu Val Ala Thr Ser Ala Thr Phe Ser Thr Glu Asp		
15	930	935	940
	Arg Arg Leu Thr Leu Ala Ser Lys Pro Lys Thr Ser Gln Pro Val Tyr		
	945	950	955 960
	Arg Glu Arg Ile Ala Tyr Thr Tyr Met Asp Glu Asp Leu Pro Thr Thr		
	965	970	975
20	Glu Tyr Ile Ser Pro Asn Glu Asp Gly Thr Phe Thr Leu Pro Glu Glu		
	980	985	990
	Ala Glu Thr Met Glu Gly Ala Thr Val Pro Leu Lys Met Ser Asp Phe		
	995	1000	1005
	Thr Tyr Val Val Glu Asp Met Ala Gly Asn Ile Thr Tyr Thr Pro Val		
25	1010	1015	1020
	Thr Lys Leu Leu Glu Gly His Ser Asn Lys Pro Glu Gln Asp Gly Ser		
	1025	1030	1035 1040
	Gly Gln Thr Pro Asp Lys Lys Pro Glu Ala Lys Pro Glu Gln Asp Gly		
	1045	1050	1055
30	Ser Asp Gln Ala Pro Asp Lys Lys Pro Glu Ala Lys Pro Glu Gln Asp		
	1060	1065	1070
	Gly Ser Gly Gln Thr Pro Asp Lys Lys Pro Glu Thr Lys Pro Glu Lys		
	1075	1080	1085
	Asp Ser Ser Gly Gln Thr Pro Gly Lys Thr Pro Gln Lys Gly Gln Pro		
35	1090	1095	1100
	Ser Arg Thr Leu Glu Lys Arg Ser Ser Lys Arg Ala Leu Ala Thr Lys		
	1105	1110	1115 1120
	Ala Ser Thr Arg Asp Gln Leu Pro Thr Thr Asn Asp Lys Asp Thr Asn		
	1125	1130	1135
40	Arg Leu His Leu Leu Lys Leu Val Met Thr Thr Phe Phe Phe Gly Leu		

WO 00/34487

PCT/US99/28826

9

	1140	1145	1150
	Val Ala His Ile Phe Lys Thr Lys Arg Gln Lys Glu Thr Lys Lys		
	1155	1160	1165
5	<210> 3 <211> 1150 <212> PRT <213> Streptococcus agalactiae		
10	<400> 3		
	Leu Arg Lys Lys Gln Lys Leu Pro Phe Asp Lys Leu Ala Ile Ala Leu		
	1	5	10
	Met Ser Thr Ser Ile Leu Leu Asn Ala Gln Ser Asp Ile Lys Ala Asn		
	20	25	30
15	Thr Val Thr Glu Asp Thr Pro Ala Thr Glu Gln Thr Val Glu Thr Pro		
	35	40	45
	Gln Pro Thr Ala Val Ser Glu Glu Ala Pro Ser Ser Lys Glu Thr Lys		
	50	55	60
	Thr Pro Gln Thr Pro Ser Asp Ala Gly Glu Thr Val Ala Asp Asp Ala		
20	65	70	75
	Asn Asp Leu Ala Pro Gln Ala Pro Ala Lys Thr Ala Asp Thr Pro Ala		
	85	90	95
	Thr Ser Lys Ala Thr Ile Arg Asp Leu Asn Asp Pro Ser Gln Val Lys		
	100	105	110
25	Thr Leu Gln Glu Lys Ala Gly Lys Gly Ala Gly Thr Val Val Ala Val		
	115	120	125
	Ile Asp Ala Gly Phe Asp Lys Asn His Glu Ala Trp Arg Leu Thr Asp		
	130	135	140
	Lys Thr Lys Ala Arg Tyr Gln Ser Lys Glu Asp Leu Glu Lys Ala Lys		
30	145	150	155
	Lys Glu His Gly Ile Thr Tyr Gly Glu Trp Val Asn Asp Lys Val Ala		
	165	170	175
	Tyr Tyr His Asp Tyr Ser Lys Asp Gly Lys Thr Ala Val Asp Gln Glu		
	180	185	190
35	His Gly Thr His Val Ser Gly Ile Leu Ser Gly Asn Ala Pro Ser Glu		
	195	200	205
	Thr Lys Glu Pro Tyr Arg Leu Glu Gly Ala Met Pro Glu Ala Gln Leu		
	210	215	220
	Leu Leu Met Arg Val Glu Ile Val Asn Gly Leu Ala Asp Tyr Ala Arg		
40	225	230	235
			240

WO 00/34487

PCT/US99/28826

10

Asn Tyr Ala Gln Ala Ile Arg Asp Ala Ile Asn Leu Gly Ala Lys Val
 245 250 255
 Ile Asn Met Ser Phe Gly Asn Ala Ala Leu Ala Tyr Ala Asn Leu Pro
 260 265 270
 5 Asp Glu Thr Lys Lys Ala Phe Asp Tyr Ala Lys Ser Lys Gly Val Ser
 275 280 285
 Ile Val Thr Ser Ala Gly Asn Asp Ser Ser Phe Gly Gly Lys Thr Arg
 290 295 300
 Leu Pro Leu Ala Asp His Pro Asp Tyr Gly Val Val Gly Thr Pro Ala
 10 305 310 315 320
 Ala Ala Asp Ser Thr Leu Thr Val Ala Ser Tyr Ser Pro Asp Lys Gln
 325 330 335
 Leu Thr Glu Thr Val Arg Val Lys Thr Ala Asp Gln Gln Asp Lys Glu
 340 345 350
 15 Met Pro Val Leu Ser Thr Asn Arg Phe Glu Pro Asn Lys Ala Tyr Asp
 355 360 365
 Tyr Ala Tyr Ala Asn Arg Gly Thr Lys Glu Asp Asp Phe Lys Asp Val
 370 375 380
 Lys Gly Lys Ile Ala Leu Ile Glu Arg Gly Asp Ile Asp Phe Lys Asp
 20 385 390 395 400
 Lys Ile Ala Lys Ala Lys Lys Ala Gly Ala Val Gly Val Leu Ile Tyr
 405 410 415
 Asp Asn Gln Asp Lys Gly Phe Pro Ile Glu Leu Pro Asn Val Asp Gln
 420 425 430
 25 Met Pro Ala Ala Phe Ile Ser Arg Lys Asp Gly Leu Leu Leu Lys Asp
 435 440 445
 Asn Pro Gln Lys Thr Ile Thr Phe Asn Ala Thr Pro Lys Val Leu Pro
 450 455 460
 Thr Ala Ser Gly Thr Lys Leu Ser Arg Phe Ser Ser Trp Gly Leu Thr
 30 465 470 475 480
 Ala Asp Gly Asn Ile Lys Pro Asp Ile Ala Ala Pro Gly Gln Asp Ile
 485 490 495
 Leu Ser Ser Val Ala Asn Asn Lys Tyr Ala Lys Leu Ser Gly Thr Ser
 500 505 510
 35 Met Ser Ala Pro Leu Val Ala Gly Ile Met Gly Leu Leu Gln Lys Gln
 515 520 525
 Tyr Glu Thr Gln Tyr Pro Asp Met Thr Pro Ser Glu Arg Leu Asp Leu
 530 535 540
 Ala Lys Lys Val Leu Met Ser Ser Ala Thr Ala Leu Tyr Asp Glu Asp
 40 545 550 555 560

WO 00/34487

PCT/US99/28826

11

Glu Lys Ala Tyr Phe Ser Pro Arg Gln Gln Gly Ala Gly Ala Val Asp
 565 570 575
 Ala Lys Lys Ala Ser Ala Ala Thr Met Tyr Val Thr Asp Lys Asp Asn
 580 585 590
 5 Thr Ser Ser Lys Val His Leu Asn Asn Val Ser Asp Lys Phe Glu Val
 595 600 605
 Thr Val Asn Val His Asn Lys Ser Asp Lys Pro Gln Glu Leu Tyr Tyr
 610 615 620
 Gln Ala Thr Val Gln Thr Asp Lys Val Asp Gly Lys His Phe Ala Leu
 10 625 630 635 640
 Ala Pro Lys Val Leu Tyr Glu Ala Ser Trp Gln Lys Ile Thr Ile Pro
 645 650 655
 Ala Asn Ser Ser Lys Gln Val Thr Val Pro Ile Asp Ala Ser Arg Phe
 660 665 670
 15 Ser Lys Asp Leu Leu Ala Gln Met Lys Asn Gly Tyr Phe Leu Glu Gly
 675 680 685
 Phe Val Arg Phe Lys Gln Asp Pro Lys Lys Glu Glu Leu Met Ser Ile
 690 695 700
 Pro Tyr Ile Gly Phe Arg Gly Asp Phe Gly Asn Leu Ser Ala Leu Glu
 20 705 710 715 720
 Lys Pro Ile Tyr Asp Ser Lys Asp Gly Ser Ser Tyr Tyr His Glu Ala
 725 730 735
 Asn Ser Asp Ala Lys Asp Gln Leu Asp Gly Asp Gly Leu Gln Phe Tyr
 740 745 750
 25 Ala Leu Lys Asn Asn Phe Thr Ala Leu Thr Thr Glu Ser Asn Pro Trp
 755 760 765
 Thr Ile Ile Lys Ala Val Lys Glu Gly Val Glu Asn Ile Glu Asp Ile
 770 775 780
 Glu Ser Ser Glu Ile Thr Glu Thr Ile Leu Ala Gly Thr Phe Ala Lys
 30 785 790 795 800
 Gln Asp Asp Asp Ser His Tyr Tyr Ile His Arg His Ala Asn Gly Lys
 805 810 815
 Pro Tyr Ala Ala Ile Ser Pro Asn Gly Asp Gly Asn Arg Asp Tyr Val
 820 825 830
 35 Gln Phe Gln Gly Thr Phe Leu Arg Asn Ala Lys Asn Leu Val Ala Glu
 835 840 845
 Val Leu Asp Lys Glu Gly Asn Val Val Trp Thr Ser Glu Val Thr Glu
 850 855 860
 Gln Val Val Lys Asn Tyr Asn Asn Asp Leu Ala Ser Thr Leu Gly Ser
 40 865 870 875 880

WO 00/34487

PCT/US99/28826

12

Thr Arg Phe Glu Lys Thr Arg Trp Asp Gly Lys Asp Lys Asp Gly Lys
 885 890 895
 Val Val Ala Asn Gly Thr Tyr Thr Tyr Arg Val Arg Tyr Thr Pro Ile
 900 905 910
 5 Ser Ser Gly Ala Lys Glu Gln His Thr Asp Phe Asp Val Ile Val Asp
 915 920 925
 Asn Thr Thr Pro Glu Val Ala Thr Ser Ala Thr Phe Ser Thr Glu Asp
 930 935 940
 Arg Arg Leu Thr Leu Ala Ser Lys Pro Lys Thr Ser Gln Pro Val Tyr
 10 945 950 955 960
 Arg Glu Arg Ile Ala Tyr Thr Tyr Met Asp Glu Asp Leu Pro Thr Thr
 965 970 975
 Glu Tyr Ile Ser Pro Asn Glu Asp Gly Thr Phe Thr Leu Pro Glu Glu
 980 985 990
 15 Ala Glu Thr Thr Glu Gly Ala Thr Val Pro Leu Lys Met Ser Asp Phe
 995 1000 1005
 Thr Tyr Val Val Glu Asp Met Ala Gly Asn Ile Thr Tyr Thr Pro Val
 1010 1015 1020
 Thr Lys Leu Leu Glu Gly His Ser Asn Lys Pro Glu Gln Asp Gly Ser
 20 1025 1030 1035 1040
 Asp Gln Ala Pro Asp Lys Lys Pro Glu Ala Lys Pro Glu Gln Asp Gly
 1045 1050 1055
 Ser Gly Gln Thr Pro Asp Lys Lys Thr Glu Thr Lys Pro Glu Lys Asp
 1060 1065 1070
 25 Ser Ser Gly Gln Thr Pro Gly Lys Thr Pro Gln Lys Gly Gln Pro Ser
 1075 1080 1085
 Arg Thr Leu Glu Lys Arg Ser Ser Lys Arg Ala Leu Ala Thr Lys Ala
 1090 1095 1100
 Ser Thr Arg Asp Gln Leu Pro Thr Thr Asn Asp Lys Asp Thr Asn Arg
 30 1105 1110 1115 1120
 Leu His Leu Leu Lys Leu Val Met Thr Thr Phe Phe Leu Gly Leu Val
 1125 1130 1135
 Ala His Ile Phe Lys Thr Lys Arg Gln Lys Glu Thr Lys Lys
 1140 1145 1150

35

<210> 4

<211> 31

<212> DNA

<213> Streptococcus pyogenes

40

WO 00/34487

PCT/US99/28826

13

<400> 4

ggggggggaat tcgtagcggg tatcatggga c

31

<210> 5

5

<211> 31

<212> DNA

<213> Streptococcus pyogenes

<400> 5

10 gggggggaat tcgggtgctg caatatctgg c

31

<210> 6

<211> 17

<212> DNA

15

<213> Streptococcus pyogenes

<400> 6

gtaaaacgac ggccagt

17

20

<210> 7

<211> 19

<212> DNA

<213> Streptococcus pyogenes

25

<400> 7

aaggacgaca cattgcgta

19

<210> 8

<211> 31

30

<212> DNA

<213> Streptococcus pyogenes

<400> 8

ccccccggat ccacaaaac cccacaaact c

31

35

<210> 9

<211> 18

<212> DNA

<213> Streptococcus pyogenes

40

WO 00/34487

PCT/US99/28826

14

<400> 9

gagtggccct ccaatagc

18

<210> 10

5

<211> 35

<212> DNA

<213> Streptococcus pyogenes

<400> 10

10 ccccccgat ccaatactgt gacagaagac actcc

35

<210> 11

<211> 25

<212> DNA

15

<213> Streptococcus pyogenes

<400> 11

tttctggaac tagtatgtct gcgcc

25

20

<210> 12

<211> 41

<212> DNA

<213> Streptococcus pyogenes

25

<400> 12

ccccccctcg agatgtaaac gatttgtatc cttgtcatta g

41

<210> 13

<211> 25

30

<212> DNA

<213> Streptococcus pyogenes

<400> 13

cagtgattga tgctgggtttt gataa

25

35

<210> 14

<211> 18

<212> DNA

<213> Streptococcus pyogenes

40

WO 00/34487

PCT/US99/28826

15

<400> 14

agctactatc agcaccag

18

<210> 15

5

<211> 38

<212> DNA

<213> Streptococcus pyogenes

<400> 15

10 cccccgaat tcattactgt gacagaagac actcctgc

38

<210> 16

<211> 39

<212> DNA

15

<213> Streptococcus pyogenes

<400> 16

ccccccggat ccttattggt ctggtttatt agagtggcc

39

20

<210> 17

<211> 33

<212> DNA

<213> Streptococcus pyogenes

25

<400> 17

attgctgctg gttttgataa aaatcatgaa gcg

33

<210> 18

<211> 18

30

<212> DNA

<213> Streptococcus pyogenes

<400> 18

cactgcaaca acagtccc

18

35

<210> 19

<211> 18

<212> DNA

<213> Streptococcus pyogenes

40

WO 00/34487

PCT/US99/28826

17

	50		55		60											
	Thr	Pro	Gln	Thr	Pro	Asp	Asp	Ala	Glu	Glu	Thr	Ile	Ala	Asp	Asp	Ala
	65				70				75							80
	Asn	Asp	Leu	Ala	Pro	Gln	Ala	Pro	Ala	Lys	Thr	Ala	Asp	Thr	Pro	Ala
5					85				90							95
	Thr	Ser	Lys	Ala	Thr	Ile	Arg	Asp	Leu	Asn	Asp	Pro	Ser	Gln	Val	Lys
					100				105							110
	Thr	Leu	Gln	Glu	Lys	Ala	Gly	Lys	Gly	Ala	Gly	Thr	Val	Val	Ala	Val
					115				120							125
10	Ile	Asp	Ala	Gly	Phe	Asp	Lys	Asn	His	Glu	Ala	Trp	Arg	Leu	Thr	Asp
					130				135							140
	Lys	Thr	Lys	Ala	Arg	Tyr	Gln	Ser	Lys	Glu	Asp	Leu	Glu	Lys	Ala	Lys
					145				150							160
	Lys	Glu	His	Gly	Ile	Thr	Tyr	Gly	Glu	Trp	Val	Asn	Asp	Lys	Val	Ala
15					165				170							175
	Tyr	Tyr	His	Asp	Tyr	Ser	Lys	Asp	Gly	Lys	Thr	Ala	Val	Asp	Gln	Glu
					180				185							190
	His	Gly	Thr	His	Val	Ser	Gly	Ile	Leu	Ser	Gly	Asn	Ala	Pro	Ser	Glu
					195				200							205
20	Thr	Lys	Glu	Pro	Tyr	Arg	Leu	Glu	Gly	Ala	Met	Pro	Glu	Ala	Gln	Leu
					210				215							220
	Leu	Leu	Met	Arg	Val	Glu	Ile	Val	Asn	Gly	Leu	Ala	Asp	Tyr	Ala	Arg
					225				230							240
	Asn	Tyr	Ala	Gln	Ala	Ile	Ile	Asp	Ala	Val	Asn	Leu	Gly	Ala	Lys	Val
25					245				250							255
	Ile	Asn	Met	Ser	Phe	Gly	Asn	Ala	Ala	Leu	Ala	Tyr	Ala	Asn	Leu	Pro
					260				265							270
	Asp	Glu	Thr	Lys	Lys	Ala	Phe	Asp	Tyr	Ala	Lys	Ser	Lys	Gly	Val	Ser
					275				280							285
30	Ile	Val	Thr	Ser	Ala	Gly	Asn	Asp	Ser	Ser	Phe	Gly	Gly	Lys	Thr	Arg
					290				295							300
	Leu	Pro	Leu	Ala	Asp	His	Pro	Asp	Tyr	Gly	Val	Val	Gly	Thr	Pro	Ala
					305				310							320
	Ala	Ala	Asp	Ser	Thr	Leu	Thr	Val	Ala	Ser	Tyr	Ser	Pro	Asp	Lys	Gln
35					325				330							335
	Leu	Thr	Glu	Thr	Ala	Thr	Val	Lys	Thr	Ala	Asp	Gln	Gln	Asp	Lys	Glu
					340				345							350
	Met	Pro	Val	Leu	Ser	Thr	Asn	Arg	Phe	Glu	Pro	Asn	Lys	Ala	Tyr	Asp
					355				360							365
40	Tyr	Ala	Tyr	Ala	Asn	Arg	Gly	Met	Lys	Glu	Asp	Asp	Phe	Lys	Asp	Val

WO 00/34487

PCT/US99/28826

18

	370		375		380														
	Lys	Gly	Lys	Ile	Ala	Leu	Ile	Glu	Arg	Gly	Asp	Ile	Asp	Phe	Lys	Asp			
	385					390					395					400			
	Lys	Ile	Ala	Asn	Ala	Lys	Lys	Ala	Gly	Ala	Val	Gly	Val	Leu	Ile	Tyr			
5				405						410					415				
	Asp	Asn	Gln	Asp	Lys	Gly	Phe	Pro	Ile	Glu	Leu	Pro	Asn	Val	Asp	Gln			
				420						425					430				
	Met	Pro	Ala	Ala	Phe	Ile	Ser	Arg	Lys	Asp	Gly	Leu	Leu	Leu	Lys	Glu			
				435						440					445				
10	Asn	Pro	Gln	Lys	Thr	Ile	Thr	Phe	Asn	Ala	Thr	Pro	Lys	Val	Leu	Pro			
				450						455					460				
	Thr	Ala	Ser	Gly	Thr	Lys	Leu	Ser	Arg	Phe	Ser	Ser	Trp	Gly	Leu	Thr			
	465					470					475				480				
	Ala	Asp	Gly	Asn	Ile	Lys	Pro	Asp	Ile	Ala	Ala	Pro	Gly	Gln	Asp	Ile			
15				485						490					495				
	Leu	Ser	Ser	Val	Ala	Asn	Asn	Lys	Tyr	Ala	Lys	Leu	Ser	Gly	Thr	Ser			
				500						505					510				
	Met	Ser	Ala	Pro	Leu	Val	Ala	Gly	Ile	Met	Gly	Leu	Leu	Gln	Lys	Gln			
				515						520					525				
20	Tyr	Glu	Thr	Gln	Tyr	Pro	Asp	Met	Thr	Pro	Ser	Glu	Arg	Leu	Asp	Leu			
				530						535					540				
	Ala	Lys	Lys	Val	Leu	Met	Ser	Ser	Ala	Thr	Ala	Leu	Tyr	Asp	Glu	Asp			
	545					550					555				560				
	Glu	Lys	Ala	Tyr	Phe	Ser	Pro	Arg	Gln	Gln	Gly	Ala	Gly	Ala	Val	Asp			
25				565						570					575				
	Ala	Lys	Lys	Ala	Ser	Ala	Ala	Thr	Met	Tyr	Val	Thr	Asp	Lys	Asp	Asn			
				580						585					590				
	Thr	Ser	Ser	Lys	Val	His	Leu	Asn	Asn	Val	Ser	Asp	Lys	Phe	Glu	Val			
				595						600					605				
30	Thr	Val	Thr	Val	His	Asn	Lys	Ser	Asp	Lys	Pro	Gln	Glu	Leu	Tyr	Tyr			
				610						615					620				
	Gln	Ala	Thr	Val	Gln	Thr	Asp	Lys	Val	Asp	Gly	Lys	Leu	Phe	Ala	Leu			
	625					630					635				640				
	Ala	Pro	Lys	Ala	Leu	Tyr	Glu	Ala	Ser	Trp	Gln	Lys	Ile	Thr	Ile	Pro			
35				645						650					655				
	Ala	Asn	Ser	Ser	Lys	Gln	Val	Thr	Ile	Pro	Ile	Asp	Val	Ser	Gln	Phe			
				660						665					670				
	Ser	Lys	Asp	Leu	Leu	Ala	Pro	Met	Lys	Asn	Gly	Tyr	Phe	Leu	Glu	Gly			
				675						680					685				
40	Phe	Val	Arg	Phe	Lys	Gln	Asp	Pro	Thr	Lys	Glu	Glu	Leu	Met	Ser	Ile			

WO 00/34487

PCT/US99/28826

19

	690		695		700	
	Pro Tyr Ile Gly Phe Arg Gly Asp Phe Gly Asn Leu Ser Ala Leu Glu					
	705		710		715	720
	Lys Pro Ile Tyr Asp Ser Lys Asp Gly Ser Ser Tyr Tyr His Glu Ala					
5		725		730		735
	Asn Ser Asp Ala Lys Asp Gln Leu Asp Gly Asp Gly Leu Gln Phe Tyr					
		740		745		750
	Ala Leu Lys Asn Asn Phe Thr Ala Leu Thr Thr Glu Ser Asn Pro Trp					
		755		760		765
10	Thr Ile Ile Lys Ala Val Lys Glu Gly Val Glu Asn Ile Glu Asp Ile					
		770		775		780
	Glu Ser Ser Glu Ile Thr Glu Thr Ile Phe Ala Gly Thr Phe Ala Lys					
		785		790		800
	Gln Asp Asp Asp Ser His Tyr Tyr Ile His Arg His Ala Asn Gly Lys					
15		805		810		815
	Pro Tyr Ala Ala Ile Ser Pro Asn Gly Asp Gly Asn Arg Asp Tyr Val					
		820		825		830
	Gln Phe Gln Gly Thr Phe Leu Arg Asn Ala Lys Asn Leu Val Ala Glu					
		835		840		845
20	Val Leu Asp Lys Glu Gly Asn Val Val Trp Thr Ser Glu Val Thr Glu					
		850		855		860
	Gln Val Val Lys Asn Tyr Asn Asn Asp Leu Ala Ser Thr Leu Gly Ser					
		865		870		880
	Thr Arg Phe Glu Lys Thr Arg Trp Asp Gly Lys Asp Lys Asp Gly Lys					
25		885		890		895
	Val Val Ala Asn Gly Thr Tyr Thr Tyr Arg Val Arg Tyr Thr Pro Ile					
		900		905		910
	Ser Ser Gly Ala Lys Glu Gln His Thr Asp Phe Asp Val Ile Val Asp					
		915		920		925
30	Asn Thr Thr Pro Glu Val Ala Thr Ser Ala Thr Phe Ser Thr Glu Asp					
		930		935		940
	Arg Arg Leu Thr Leu Ala Ser Lys Pro Lys Thr Ser Gln Pro Val Tyr					
		945		950		960
	Arg Glu Arg Ile Ala Tyr Thr Tyr Met Asp Glu Asp Leu Pro Thr Thr					
35		965		970		975
	Glu Tyr Ile Ser Pro Asn Glu Asp Gly Thr Phe Thr Leu Pro Glu Glu					
		980		985		990
	Ala Glu Thr Met Glu Gly Ala Thr Val Pro Leu Lys Met Ser Asp Phe					
		995		1000		1005
40	Thr Tyr Val Val Glu Asp Met Ala Gly Asn Ile Thr Tyr Thr Pro Val					

WO 00/34487

PCT/US99/28826

20

	1010	1015	1020
	Thr Lys Leu Leu Glu Gly His Ser Asn Lys Pro Glu Gln Asp Gly Ser		
	1025	1030	1035 1040
	Asp Gln Ala Pro Asp Lys Lys Pro Glu Thr Lys Pro Glu Gln Asp Gly		
5	1045	1050	1055
	Ser Gly Gln Ala Pro Asp Lys Lys Pro Glu Thr Lys Pro Glu Gln Asp		
	1060	1065	1070
	Gly Ser Gly Gln Thr Pro Asp Lys Lys Pro Glu Thr Lys Pro Glu Gln		
	1075	1080	1085
10	Asp Gly Ser Gly Gln Thr Pro Asp Lys Lys Pro Glu Thr Lys Pro Glu		
	1090	1095	1100
	Lys Asp Ser Ser Gly Gln Thr Pro Gly Lys Thr Pro Gln Lys Gly Gln		
	1105	1110	1115 1120
	Pro Ser Arg Thr Leu Glu Lys Arg Ser Ser Lys Arg Ala Leu Ala Thr		
15	1125	1130	1135
	Lys Ala Ser Thr Arg Asp Gln Leu Pro Thr Thr Asn Asp Lys Asp Thr		
	1140	1145	1150
	Asn Arg Leu His Leu Leu Lys Leu Val Met Thr Thr Phe Phe Leu Gly		
	1155	1160	1165
20	Leu Val Ala His Ile Phe Lys Thr Lys Arg Thr Lys Lys		
	1170	1175	1180

WHAT IS CLAIMED IS:

1. A vaccine comprising an immunogenic amount of an enzymatically inactive streptococcal C5a peptidase (SCP), which amount is effective to immunize a susceptible mammal against β -hemolytic Streptococcus in combination with a physiologically-acceptable, non-toxic vehicle, wherein the SCP has a substitution at one or more of amino acid residues corresponding to amino acids 260, 261, 262, 415, 416, 417, 130, 193, 295 or 512 of SEQ ID No:1.
2. The vaccine of claim 1 wherein the SCP is expressed from an isolated DNA sequence encoding SCP.
3. The vaccine of claim 2 wherein the SCP comprises a specificity crevice or catalytic domain.
4. The vaccine of claim 3 wherein the SCP comprises a specificity crevice.
5. The vaccine of claim 4 wherein the SCP comprises contiguous amino acid residues from about residue 260 to residue 417 of SEQ ID No:1.
6. The vaccine of claim 4 wherein the SCP comprises one or more of amino acid residues 260, 261, 262, 415, 416 or 417 of SEQ ID No:1.
7. The vaccine of claim 1, wherein the substitution is a conserved substitution.
8. The vaccine of claim 3 wherein the SCP comprises a catalytic domain.
9. The vaccine of claim 8 wherein the SCP comprises contiguous amino acid residues from about residue 130 to residue 512 of SEQ ID No:1.
10. The vaccine of claim 8 wherein the SCP comprises one or more of amino acid residues 130, 193, 295 or 512 of SEQ ID No:1.

11. The vaccine of claim 1 wherein the enzymatically inactive SCP has reduced binding activity to C5a as compared to the binding activity to C5a of wild-type SCP.
12. The vaccine of claim 1 which further comprises an effective amount of an immunological adjuvant.
13. The vaccine of claim 1 wherein the mammal is a of human, dog, bovine, porcine or horse.
14. The vaccine of claim 13 wherein the mammal is human.
15. The vaccine of claim 1 wherein the β -hemolytic Streptococcus is a group A Streptococcus, group B Streptococcus, group C Streptococcus or group G Streptococcus.
16. The vaccine according to claim 15 wherein the β -hemolytic Streptococcus is Group A Streptococcus.
17. The vaccine of claim 1 wherein the enzymatically inactive SCP is from group A Streptococcus, group B Streptococcus, group C Streptococcus or group G Streptococcus.
18. The vaccine according to claim 17 wherein the Streptococcus is Group A Streptococcus.
19. The vaccine of claim 1, which comprises an enzymatically inactive SCP conjugated or linked to a peptide.
20. The vaccine of claim 1, which comprises an enzymatically inactive SCP conjugated or linked to a polysaccharide.
21. A use of the vaccine of any one of claims 1 to 20 for protecting a susceptible mammal against β -hemolytic Streptococcus colonization or infection.

22. An isolated and purified peptide comprising an enzymatically inactive Streptococcal C5a peptidase (SCP), wherein the SCP has a substitution at one or more of amino acid residues corresponding to amino acids 260, 261, 262, 415, 416, 417, 130, 193, 295 or 512 of SEQ ID No:1.
23. The peptide of claim 22 wherein the peptide comprises enzymatically inactive streptococcal C5a peptidase (SCP) that has reduced binding activity to C5a as compared to the binding activity to C5a of wild-type SCP.
24. The peptide of claim 22 wherein the SCP is expressed from an isolated DNA sequence encoding SCP.
25. The peptide of claim 22 wherein the SCP has a specificity crevice or catalytic domain.
26. The peptide of claim 25 wherein the SCP comprises a specificity crevice.
27. The peptide of claim 26 wherein the SCP comprises contiguous amino acid residues from about residue 260 to residue 417 of SEQ ID No:1.
28. The peptide of claim 25 wherein the SCP has a catalytic domain.
29. The peptide of claim 28 wherein the SCP comprises contiguous amino acid residues from about residue 130 to residue 512 of SEQ ID No:1.
30. The peptide of claim 28 wherein the SCP comprises one or more of amino acid residues 130, 193, 295 or 512 of SEQ ID No:1.
31. The peptide of claim 28 wherein the SCP further comprises the region of SCP between the catalytic domain and the cell wall insert.

32. The peptide of claim 22 wherein the enzymatically inactive SCP has a substitution at one or more of amino acid residues 260, 261, 262, 415, 416, 417, 130, 193, 295 or 512 of SEQ ID No:1.
33. The peptide of claim 32 wherein the substitution is a conserved substitution.
34. The peptide of claim 22 wherein the enzymatically inactive SCP is from group A Streptococcus, group B Streptococcus, group C Streptococcus or group G Streptococcus.
35. The peptide according to claim 34 wherein the Streptococcus is Group A Streptococcus.
36. An isolated and purified polynucleotide comprising a nucleotide sequence encoding an enzymatically inactive Streptococcal C5a peptidase (SCP), wherein the SCP has a substitution at one or more of amino acid residues corresponding to amino acids 260, 261, 262, 415, 416, 417, 130, 193, 295 or 512 of SEQ ID No:1.
37. The polynucleotide sequence of claim 36 wherein the polynucleotide is DNA.
38. The polynucleotide sequence of claim 36 wherein the polynucleotide is RNA.
39. The polynucleotide sequence of claim 37 wherein the SCP comprises a specificity crevice or catalytic domain.
40. The polynucleotide sequence of claim 39 wherein the SCP comprises a specificity crevice.
41. The polynucleotide of claim 40 wherein the SCP comprises contiguous amino acid residues from about residue 260 to residue 417 of SEQ ID No:1.
42. The polypeptide of claim 40 wherein the SCP comprises one or more of amino acid residues 260, 261, 262, 415, 416 or 417 of SEQ ID No:1.

43. The polynucleotide sequence of claim 39 wherein the SCP comprises a catalytic domain.
44. The polynucleotide of claim 43 wherein the SCP comprises contiguous amino acid residues from about residue 130 to residue 512 of SEQ ID No:1.
45. The polynucleotide of claim 43 wherein the SCP comprises one or more of amino acid residues 130, 193, 295 or 512 of SEQ ID No:1.
46. The polynucleotide of claim 36 wherein the substitution is a conserved substitution.
47. The polynucleotide of claim 36 wherein the SCP is from group A Streptococcus, group B Streptococcus, group C Streptococcus or group G Streptococcus.
48. The polynucleotide according to claim 47 wherein the Streptococcus is Group A Streptococcus.
49. The polynucleotide of claim 37 wherein the polynucleotide encodes an enzymatically inactive streptococcal C5a peptidase (SCP) that has reduced binding activity as compared to wild-type SCP.
50. A composition comprising an enzymatically inactive streptococcal C5a peptidase (SCP) of any one of claims 22-35 conjugated or linked to one or more peptides, and a vehicle.
51. The composition of claim 50 wherein the peptide is keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), ovalbumin, human serum albumin, human gamma globulin, chicken immunoglobulin G or bovine gamma globulin.
52. The composition of claim 50 wherein the peptide is a protein of another pathogen.

53. The composition of claim 52 wherein the protein of another pathogen is a *Streptococcus pneumoniae* protein.
54. A composition comprising an enzymatically inactive streptococcal C5a peptidase (SCP) of any one of claims 22-35 conjugated or linked to one or more polysaccharides, and a vehicle.
55. The composition of claim 54 wherein the polysaccharide is a group A Streptococci polysaccharide, a group B Streptococci polysaccharide, a group C Streptococci polysaccharide or a group G Streptococci polysaccharide.
56. The composition of claim 54 wherein the polysaccharide is a polysaccharide of another pathogen.
57. The composition of claim 56 wherein the polysaccharide of another pathogen is a *Streptococcus pneumoniae* polysaccharide.
58. The vaccine of claim 11 wherein the binding activity is reduced by at least 50%.
59. The peptide of claim 23 wherein the binding activity is reduced by at least 50%.
60. The polynucleotide of claim 49 wherein the binding activity is reduced by at least 50%.
61. The composition of claim 50 wherein the vehicle is a pharmacologically acceptable vehicle.
62. The composition of claim 54 wherein the vehicle is a pharmacologically acceptable vehicle.




FIG. 1

WO 00/34487

PCT/US99/28826

2/11

1
 SCPA49 LRKKQKLPFDKLAIALMSTSILLNAQSDIKANTVTEDTPATEQAVEIPQPTTVSEEVSS
 SCPA12 -----V-----A-----
 SCPB -----T-----A-----A-----

61
 KETKTPQTPDDAEETVADDANDLAPQAPAKTPDTSATSKATIRDLNDPSQVKTLEKAGK
 -----I-----A--P-----
 -----S--G-----A--P-----

121 *
 GAGTVVAVIDAGFDKNHEAWRLTDKAKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHD
 -----T-----
 -----T-----

181 *
 YSKDGKTAVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLHRVEIVNGLADYAR

241
 NYAQAIRDAVNLGAKVINMSFGNAALAYANLPDETCKPFVYAKSKGVRIVTTAGNDSSFG
 -----A-D-----S--S-----
 -----I-----A-D-----S--S-----

301
 GKTRLPLADHPDYGVVGTAAADSTLTVASYSFDNQLTETAMVKTDQDQDKEMPVLSTNR
 -----K-----
 -----K-----VR---A-----

361
 FEPNKAYDYAYANRGHKEDDFKDVKGKIALIERSDIDFIDKIANAKKAGAVGVLIYDNQD
 -----G--K--V-----
 -----T-----G--K--K-----

421
 KGFPIELPNVDQHPAAFISRKDGLLLKDNSQKTITFNATPKVLPTASGKLSRFSSWGLT
 -----P-----
 -----P-----

481 *
 ADGNIKPDIAAPGQDILSSAANNKYAKLSGTSHSAPLVAVIMGLLQKQYETQYPMTOSE
 -----V-----G-----P-----
 -----V-----G-----P-----

541
 RLDLAKKVLMSATALYDEDEKAYFSPROQGAGAVDAKKASEATHYVIDKDNISSKVHLN
 -----A-----
 -----A-----

601
 NVSDKFEVIVIVHNKSDKPHELYQATVQIDKVDGKHFAKALIKALITSWQKITIPANSS
 -----Q-----V-Y-A-----
 -----N-----Q-----V-Y-A-----

661
 KQVTIPIDISQFSKDLAQMKNGYFLEGFVRIKQDPIKEELHSIPYIGFRGDFGNLSALE
 ---V---A-R-----F-----V-----
 ---V---A-R-----F---K-----

721
 KPLYDSKDGSSYYHEEISDAKDQLDGDGLQFYALKNDFTALTTESNPNTIINVVKEGVEN
 --I-----AN-----N-----KA-----
 --I-----AN-----N-----KA-----

781
 IEDIESSEITETIFAGTFAKQDDRHYYIHRHANGKPYAAISPNGDGNRDYVQFHGTFLR
 -----S-----E-----Q-----
 -----L-----S-----Q-----

841
 NAKNLVAEVLKKEGNNVKISEVIEQVVKYNNDLASTLGSTRFEISRHDGKDKDAKVAN
 -----KT-----G-----
 -----KT-----G-----

901
 GTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSIEDRRLTLASKPQISQPVY
 -----K-----
 -----K-----

961
 RERIAITYMDEDLPTIEYISPNEGTFTLPEEAETMEGATVPLKMSDFIYVVEDMAGNIT

 -----T-----

1021
 YTPVIKLEGHSENKPEQDGSQAPDKKPKETKPEQDGSQAPDKKPKETKPGODGSGQTPDK
 -----G-T-----A-----A-E-----
 -----A-----A-E-----

1081
 KPETKPEKDSSGQTPGKTPQKGQPSRTLEKRSSKRALATKASTRDQLPTINDKDTNRLHL


 -----T-----

1141
 LKLVMTTFFLGLVAHIFKTKR...TED
 -----F-----QKE-KK
 -----QKE-KK

FIG. 2

SUBSTITUTE SHEET (RULE 26)

FIG. 3







FIG. 4



6/11




FIG. 6

7/11




FIG. 7

8/11




FIG. 8

WO 00/34487

PCT/US99/28826

9/11




FIG. 9A




FIG. 9B

WO 00/34487

PCT/US99/28826

10/11




FIG. 10B




FIG. 10A

11/11




FIG. 11




FIG. 12

